

# A serological assay to detect SARS-CoV-2 seroconversion

Nature Medicine

26, 1033-1036

DOI: [10.1038/s41591-020-0913-5](https://doi.org/10.1038/s41591-020-0913-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?. AAPS Journal, 2020, 22, 127.	4.4	3
2	The Rapid Coronavirus Antibody Test: Can We Improve Accuracy?. Frontiers in Medicine, 2020, 7, 569.	2.6	12
3	Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers. Journal of Clinical Medicine, 2020, 9, 3188.	2.4	68
4	Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity, 2020, 53, 925-933.e4.	14.3	301
5	Impact of primary culture: A true positive culture rate mystery. Transfusion, 2020, 60, 2459-2460.	1.6	0
6	Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany. Frontiers in Public Health, 2020, 8, 570543.	2.7	16
7	Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip. Biosensors and Bioelectronics, 2020, 169, 112578.	10.1	207
8	Biosensor and molecular-based methods for the detection of human coronaviruses: A review. Molecular and Cellular Probes, 2020, 54, 101662.	2.1	40
9	Diagnosis of COVID-19: facts and challenges. New Microbes and New Infections, 2020, 38, 100761.	1.6	13
10	Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. Cell Reports Medicine, 2020, 1, 100078.	6.5	160
11	Magnetic-Nanosensor-Based Virus and Pathogen Detection Strategies before and during COVID-19. ACS Applied Nano Materials, 2020, 3, 9560-9580.	5.0	81
12	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nature Protocols, 2020, 15, 3699-3715.	12.0	291
13	Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation. Biosensors and Bioelectronics, 2020, 169, 112572.	10.1	52
14	S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. MBio, 2020, 11, .	4.1	188
15	Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell, 2020, 183, 982-995.e14.	28.9	440
16	Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26382-26388.	7.1	340
17	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Reports Medicine, 2020, 1, 100126.	6.5	200
18	Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein. MBio, 2020, 11, .	4.1	61

#	ARTICLE	IF	CITATIONS
19	Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. European Journal of Immunology, 2020, 50, 2025-2040.	2.9	188
20	“America First” Will Destroy U.S. Science. Cell, 2020, 183, 841-844.	28.9	1
21	Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS ONE, 2020, 15, e0241104.	2.5	158
22	In Utero Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm Infant. AJP Reports, 2020, 10, e270-e274.	0.7	9
24	Review of chest CT manifestations of COVID-19 infection. European Journal of Radiology Open, 2020, 7, 100239.	1.6	47
25	Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. International Journal of Infectious Diseases, 2020, 101, 220-225.	3.3	55
26	Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature, 2020, 588, 315-320.	27.8	1,035
27	Benefits and limitations of serological assays in COVID-19 infection. Indian Journal of Tuberculosis, 2020, 67, S163-S166.	0.7	64
28	Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Science Immunology, 2020, 5, .	11.9	714
29	Early diagnosis and population prevention of coronavirus disease 2019. Current Opinion in HIV and AIDS, 2020, 15, 345-350.	3.8	2
30	Non-synonymous mutations of SARS-CoV-2 leads epitope loss and segregates its variants. Microbes and Infection, 2020, 22, 598-607.	1.9	40
31	A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers. Chemical Science, 2020, 11, 12157-12164.	7.4	84
32	Point-of-Care Biosensor-Based Diagnosis of COVID-19 Holds Promise to Combat Current and Future Pandemics. ACS Applied Bio Materials, 2020, 3, 7326-7343.	4.6	123
33	SARS-CoV-2 vaccines in development. Nature, 2020, 586, 516-527.	27.8	1,659
34	Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. Lancet Microbe, The, 2020, 1, e283-e289.	7.3	133
35	Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients. Biosensors and Bioelectronics, 2020, 169, 112643.	10.1	30
36	Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell, 2020, 183, 143-157.e13.	28.9	599
37	Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology. Clinical Biochemistry, 2020, 86, 1-7.	1.9	17

#	ARTICLE	IF	CITATIONS
38	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. <i>Cell Reports Medicine</i> , 2020, 1, 100099.	6.5	61
39	Cross-reactive memory T cells and herd immunity to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2020, 20, 709-713.	22.7	229
40	SARS-CoV-2 S1 and N-based serological assays reveal rapid seroconversion and induction of specific antibody response in COVID-19 patients. <i>Scientific Reports</i> , 2020, 10, 16561.	3.3	84
41	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. <i>Frontiers in Public Health</i> , 2020, 8, 384.	2.7	13
42	Review of Viral Testing (Polymerase Chain Reaction) and Antibody/Serology Testing for Severe Acute Respiratory Syndrome-Coronavirus-2 for the Intensivist. , 2020, 2, e0154.		22
43	SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. <i>Nature Communications</i> , 2020, 11, 3581.	12.8	251
44	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature Medicine</i> , 2020, 26, 1428-1434.	30.7	400
45	Comprehensive mapping of immune perturbations associated with severe COVID-19. <i>Science Immunology</i> , 2020, 5, .	11.9	677
46	Evaluation of Six Commercial Mid- to High-Volume Antibody and Six Point-of-Care Lateral Flow Assays for Detection of SARS-CoV-2 Antibodies. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	90
47	Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges. <i>Life Sciences</i> , 2020, 257, 118058.	4.3	11
48	Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. <i>Biosensors and Bioelectronics</i> , 2020, 165, 112454.	10.1	323
49	A serological assay to detect SARS-CoV-2 antibodies in at-home collected finger-prick dried blood spots. <i>Scientific Reports</i> , 2020, 10, 20188.	3.3	58
50	Newborn Dried Blood Spots for Serologic Surveys of COVID-19. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e454-e456.	2.0	17
51	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. <i>EBioMedicine</i> , 2020, 62, 103132.	6.1	77
52	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. <i>Immunity</i> , 2020, 53, 1281-1295.e5.	14.3	285
53	A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. <i>Molecules</i> , 2020, 25, 5392.	3.8	26
54	Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2974-2978.	4.3	41
55	Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19. <i>Scientific Reports</i> , 2020, 10, 20533.	3.3	66

#	ARTICLE	IF	CITATIONS
56	Microfluidic devices for the detection of viruses: aspects of emergency fabrication during the COVID-19 pandemic and other outbreaks. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2020, 476, 20200398.	2.1	34
57	Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity. Frontiers in Medicine, 2020, 7, 592629.	2.6	54
58	Serodiagnostics for Severe Acute Respiratory Syndrome-Related Coronavirus 2. Annals of Internal Medicine, 2020, 173, 450-460.	3.9	124
59	Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. Tumori, 2021, 107, 446-451.	1.1	126
60	SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. Immunity, 2020, 53, 1245-1257.e5.	14.3	194
61	Is Vertical Transmission of SARS-CoV-2 Infection Possible in Preterm Triplet Pregnancy? A Case Series. Pediatric Infectious Disease Journal, 2020, 39, e456-e458.	2.0	6
62	Convalescent Plasma - Is it Useful for Treating SARS Co-V2 infection?. Indian Journal of Medical Microbiology, 2020, 38, 252-260.	0.8	7
63	Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic. Frontiers in Pediatrics, 2020, 8, 605807.	1.9	34
64	Assessment of serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, multicentric study. BMJ Open, 2020, 10, e041268.	1.9	19
65	Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine, 2020, 29-30, 100651.	7.1	126
66	SARS-CoV-2 Transmission among Marine Recruits during Quarantine. New England Journal of Medicine, 2020, 383, 2407-2416.	27.0	94
67	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. Microorganisms, 2020, 8, 1733.	3.6	16
68	Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands. Nature Communications, 2020, 11, 5744.	12.8	80
69	Multi-species ELISA for the detection of antibodies against SARS-CoV-2 in animals. Transboundary and Emerging Diseases, 2021, 68, 1779-1785.	3.0	66
70	Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2. Journal of Clinical Microbiology, 2020, 58, .	3.9	137
71	Measuring the Serologic Response to Severe Acute Respiratory Syndrome Coronavirus 2. Clinics in Laboratory Medicine, 2020, 40, 603-614.	1.4	12
72	SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. Journal of Infectious Diseases, 2020, 222, 1452-1461.	4.0	116
73	Beyond serosurveys: Human biology and the measurement of <sc>SARSâ€Cov</sc>-â€2 antibodies. American Journal of Human Biology, 2020, 32, e23483.	1.6	11

#	ARTICLE	IF	CITATIONS
74	Low Incidence and Mortality from SARS-CoV-2 in Southern Europe. Proposal of a hypothesis for Arthropod borne Herd immunity. Medical Hypotheses, 2020, 143, 110121.	1.5	2
75	Comprehensive Analyses of SARS-CoV-2 Transmission in a Public Health Virology Laboratory. Viruses, 2020, 12, 854.	3.3	21
76	Point-of-Use Rapid Detection of SARS-CoV-2: Nanotechnology-Enabled Solutions for the COVID-19 Pandemic. International Journal of Molecular Sciences, 2020, 21, 5126.	4.1	105
77	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nature Biotechnology, 2020, 38, 1073-1078.	17.5	1,042
78	Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine, 2020, 58, 102911.	6.1	120
79	Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clinical Microbiology and Infection, 2020, 26, 1557.e1-1557.e7.	6.0	124
80	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. Npj Vaccines, 2020, 5, 69.	6.0	121
81	A thermostable, closed SARS-CoV-2 spike protein trimer. Nature Structural and Molecular Biology, 2020, 27, 934-941.	8.2	261
82	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine, 2020, 59, 102915.	6.1	101
83	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. Immunity, 2020, 53, 724-732.e7.	14.3	267
84	Unexpected diagnosis of COVID-19-associated disorders by SARS-CoV-2-specific serology. Journal of Clinical Virology, 2020, 132, 104568.	3.1	7
85	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature, 2020, 584, 437-442.	27.8	1,742
86	Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science, 2020, 369, 1261-1265.	12.6	520
87	Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science, 2020, 370, 89-94.	12.6	1,036
88	Point-of-Care Diagnostics of COVID-19: From Current Work to Future Perspectives. Sensors, 2020, 20, 4289.	3.8	67
89	SARS-CoV-2 seroprevalence among parturient women in Philadelphia. Science Immunology, 2020, 5, .	11.9	121
90	Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nature Communications, 2020, 11, 3774.	12.8	78
91	Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies. Vaccines, 2020, 8, 443.	4.4	16

#	ARTICLE	IF	CITATIONS
92	SARS-CoV-2-specific ELISA development. Journal of Immunological Methods, 2020, 484-485, 112832.	1.4	77
93	Convalescent Plasma Therapy for COVID-19: State of the Art. Clinical Microbiology Reviews, 2020, 33, .	13.6	94
94	Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression. Physiology, 2020, 35, 288-301.	3.1	164
95	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nature Communications, 2020, 11, 4059.	12.8	266
96	<scp>Antiâ€SARSâ€CoV</scp>â€2 spike antibodies are stable in convalescent plasma when stored at 4Â° Celsius for at least 6â€weeks. Transfusion, 2020, 60, 2457-2459.	1.6	17
97	Kinetics and isotype assessment of antibodies targeting the spike protein receptorâ€binding domain of severe acute respiratory syndromeâ€coronavirusâ€2 in COVIDâ€19 patients as a function of age, biological sex and disease severity. Clinical and Translational Immunology, 2020, 9, e1189.	3.8	38
98	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, 2020, 5, 1598-1607.	13.3	1,115
99	Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. Journal of Clinical Medicine, 2020, 9, 3372.	2.4	54
100	Targeting the SARS-CoV2 nucleocapsid protein for potential therapeutics using immuno-informatics and structure-based drug discovery techniques. Biomedicine and Pharmacotherapy, 2020, 132, 110914.	5.6	24
101	Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. Journal of Experimental Medicine, 2020, 217, .	8.5	357
102	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science, 2020, 370, 1227-1230.	12.6	1,035
103	Roadmap to the Bioanalytical Testing of COVID-19: From Sample Collection to Disease Surveillance. ACS Sensors, 2020, 5, 3328-3345.	7.8	37
104	Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2020, 31, 2753-2756.	6.1	34
105	Sensitivity and specificity of SARS-CoV-2 S1 subunit in COVID-19 serology assays. Cell Discovery, 2020, 6, 75.	6.7	27
106	Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. Nature Biomedical Engineering, 2020, 4, 1188-1196.	22.5	77
107	Kidney transplantation using lymphocyte depleting induction and standard maintenance immunosuppression at the height of the SARSâ€CoVâ€2 pandemic in New York City: A singleâ€center experience. Clinical Transplantation, 2020, 34, e14055.	1.6	11
108	COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. Journal of Clinical Microbiology, 2020, 59, .	3.9	193
109	A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2020, 222, 1629-1634.	4.0	27

#	ARTICLE	IF	CITATIONS
110	Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	494
111	Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. <i>Nature Communications</i> , 2020, 11, 4378.	12.8	63
112	Detection of the SARS-CoV-2 humanized antibody with paper-based ELISA. <i>Analyst</i> , The, 2020, 145, 7680-7686.	3.5	62
113	Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 180.	17.1	222
114	Are we underestimating seroprevalence of SARS-CoV-2?. <i>BMJ</i> , The, 2020, 370, m3364.	6.0	56
115	Nanotechnology Responses to COVID-19. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000979.	7.6	128
116	Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28693.	1.5	37
117	Potential Diagnostic Systems for Coronavirus Detection: a Critical Review. <i>Biological Procedures Online</i> , 2020, 22, 21.	2.9	13
118	Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). <i>Pediatrics</i> , 2020, 146, .	2.1	113
119	Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns. <i>Journal of Immunology</i> , 2020, 205, 2342-2350.	0.8	69
120	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1390-1400.	9.1	336
121	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , 2020, 16, e1008817.	4.7	105
122	Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. <i>Nature Biomedical Engineering</i> , 2020, 4, 1180-1187.	22.5	110
123	Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25018-25025.	7.1	279
124	No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic. <i>Journal of Infectious Diseases</i> , 2020, 222, 1960-1964.	4.0	45
125	COVID-19 Infection Among Healthcare Workers: Serological Findings Supporting Routine Testing. <i>Frontiers in Medicine</i> , 2020, 7, 471.	2.6	35
126	Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. <i>Science</i> , 2020, 370, 725-730.	12.6	348
127	Sensitive and Specific Detection of SARS-CoV-2 Antibodies Using a High-Throughput, Fully Automated Liquid-Handling Robotic System. <i>SLAS Technology</i> , 2020, 25, 545-552.	1.9	22

#	ARTICLE	IF	CITATIONS
128	Seroepidemiologic Study Designs for Determining SARS-CoV-2 Transmission and Immunity. Emerging Infectious Diseases, 2020, 26, 1978-1986.	4.3	71
129	Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nature Biotechnology, 2020, 38, 1174-1183.	17.5	251
130	Immune responses during COVID-19 infection. Oncoimmunology, 2020, 9, 1807836.	4.6	103
131	Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nature Medicine, 2020, 26, 1708-1713.	30.7	405
132	Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses, 2020, 12, 1011.	3.3	54
133	Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: Experience at large transplant center in New York City. Clinical Transplantation, 2020, 34, e14089.	1.6	28
134	Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. MSphere, 2020, 5, .	2.9	62
135	Evaluation of Orthogonal Testing Algorithm for Detection of SARS-CoV-2 IgG Antibodies. Clinical Chemistry, 2020, 66, 1531-1537.	3.2	18
136	Rapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays. Journal of Proteome Research, 2020, 19, 4339-4354.	3.7	23
137	Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease. Clinical Chemistry, 2020, 66, 1562-1572.	3.2	134
138	A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathogens, 2020, 16, e1008796.	4.7	90
139	Suboptimal SARS-CoV-2-specific CD8 <sup>+</sup> T cell response associated with the prominent HLA-A*02:01 phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24384-24391.	7.1	168
140	High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay. PLoS ONE, 2020, 15, e0237833.	2.5	83
141	Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses. Clinical Infectious Diseases, 2021, 73, e2444-e2449.	5.8	137
142	Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay. Journal of Infectious Diseases, 2020, 222, 1965-1973.	4.0	13
143	A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Science Translational Medicine, 2020, 12, .	12.4	228
144	Estimating unobserved SARS-CoV-2 infections in the United States. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22597-22602.	7.1	71
145	COVID-19 diagnostic testing: Technology perspective. Clinical and Translational Medicine, 2020, 10, e158.	4.0	61

#	ARTICLE	IF	CITATIONS
146	Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer. American Journal of Clinical Pathology, 2020, 154, 620-626.	0.7	26
147	Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Frontiers in Immunology, 2020, 11, 610688.	4.8	190
148	Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures. Frontiers in Medicine, 2020, 7, 603996.	2.6	9
149	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Frontiers in Immunology, 2020, 11, 571481.	4.8	48
150	Plant Molecular Farming as a Strategy Against COVID-19 – The Italian Perspective. Frontiers in Plant Science, 2020, 11, 609910.	3.6	15
151	Corona Pandemic: Assisted Isolation and Care to Protect Vulnerable Populations May Allow Us to Shorten the Universal Lock-Down and Gradually Re-open Society. Frontiers in Public Health, 2020, 8, 562901.	2.7	2
152	Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry. Scientific Reports, 2020, 10, 21738.	3.3	49
153	Pilot Production of SARS-CoV-2 Related Proteins in Plants: A Proof of Concept for Rapid Repurposing of Indoor Farms Into Biomanufacturing Facilities. Frontiers in Plant Science, 2020, 11, 612781.	3.6	47
154	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. Vaccines, 2020, 8, 746.	4.4	6
155	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. Frontiers in Microbiology, 2020, 11, 596851.	3.5	7
156	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 2020, 8, 771.	4.4	61
157	Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. Current Protocols in Immunology, 2020, 131, e116.	3.6	111
158	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Advances, 2020, 4, 6051-6063.	5.2	105
159	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. Pathogens, 2020, 9, 1027.	2.8	20
160	Assessment of Seroconversion to SARS-CoV-2 in a Cohort of Pediatric Kidney Transplant Recipients. Frontiers in Pediatrics, 2020, 8, 601327.	1.9	6
161	Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell, 2020, 183, 1901-1912.e9.	28.9	618
162	Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome—An Observational Pilot Study. Frontiers in Immunology, 2020, 11, 581338.	4.8	75
163	Intensive diagnostic management of coronavirus disease 2019 (COVID-19) in academic settings in Japan: challenge and future. Inflammation and Regeneration, 2020, 40, 38.	3.7	3

#	ARTICLE	IF	CITATIONS
164	SARS-CoV-2 Cysteine-like Protease Antibodies Can Be Detected in Serum and Saliva of COVID-19 Seropositive Individuals. <i>Journal of Immunology</i> , 2020, 205, 3130-3140.	0.8	32
165	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. <i>Cell</i> , 2020, 183, 1508-1519.e12.	28.9	263
166	Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. <i>Viruses</i> , 2020, 12, 513.	3.3	641
167	Lessons From COVID-19 in Children: Key Hypotheses to Guide Preventative and Therapeutic Strategies. <i>Clinical Infectious Diseases</i> , 2020, 71, 2006-2013.	5.8	33
168	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	14.3	1,387
169	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115094.	1.8	293
170	The COVID-19 MS Coalition accelerating diagnostics, prognostics, and treatment. <i>Lancet</i> , The, 2020, 395, 1761-1762.	13.7	51
171	Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1256.e9-1256.e11.	6.0	101
172	On the evolutionary epidemiology of SARS-CoV-2. <i>Current Biology</i> , 2020, 30, R849-R857.	3.9	160
173	Serological differentiation between COVID-19 and SARS infections. <i>Emerging Microbes and Infections</i> , 2020, 9, 1497-1505.	6.5	89
174	The end of social confinement and COVID-19 re-emergence risk. <i>Nature Human Behaviour</i> , 2020, 4, 746-755.	12.0	197
175	Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City. <i>Journal of General Internal Medicine</i> , 2020, 35, 2485-2486.	2.6	68
176	Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. <i>Clinical Infectious Diseases</i> , 2020, 71, 2688-2694.	5.8	268
177	In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. <i>Modern Pathology</i> , 2020, 33, 2104-2114.	5.5	257
179	The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. <i>Science Immunology</i> , 2020, 5, .	11.9	772
180	Out of the Darkness, Into the Light: Value of SARS-CoV-2 Antibody Testing in Populations to Benefit Public Health and in Individuals for Peace of Mind. <i>journal of applied laboratory medicine</i> , The, 2020, 5, 1101-1106.	1.3	0
181	The COVID-19 Serology Studies Workshop: Recommendations and Challenges. <i>Immunity</i> , 2020, 53, 1-5.	14.3	71
182	Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates. <i>Vaccine</i> , 2020, 38, 5653-5658.	3.8	49

#	ARTICLE	IF	CITATIONS
183	COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds. <i>Journal of Virology</i> , 2020, 94, .	3.4	79
184	Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. <i>ELife</i> , 2020, 9, .	6.0	80
185	Antibody tests for identification of current and past infection with SARS-CoV-2. <i>The Cochrane Library</i> , 2020, 2020, CD013652.	2.8	664
186	Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests. <i>Journal of Clinical Virology</i> , 2020, 129, 104544.	3.1	73
187	Convalescent plasma therapy in patients with COVID-19. <i>Journal of Clinical Apheresis</i> , 2020, 35, 367-373.	1.3	29
188	A review on histotechnology practices in COVID-19 pathology investigations. <i>Journal of Histotechnology</i> , 2020, 43, 153-158.	0.5	2
189	Adaptive immunity to SARS-CoV-2. <i>Oxford Open Immunology</i> , 2020, 1, iqaa003.	2.8	10
190	Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease. <i>Journal of Proteome Research</i> , 2020, 19, 4219-4232.	3.7	63
191	LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins. <i>European Journal of Immunology</i> , 2020, 50, 1234-1236.	2.9	30
192	Review of Current Advances in Serologic Testing for COVID-19. <i>American Journal of Clinical Pathology</i> , 2020, 154, 293-304.	0.7	131
193	An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. <i>Current Protocols in Microbiology</i> , 2020, 58, e108.	6.5	165
194	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. <i>Cell Host and Microbe</i> , 2020, 28, 486-496.e6.	11.0	178
195	Using Serology with Models to Clarify the Trajectory of the SARS-CoV-2 Emerging Outbreak. <i>Trends in Immunology</i> , 2020, 41, 849-851.	6.8	7
196	The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review. <i>International Journal of Infectious Diseases</i> , 2020, 98, 372-380.	3.3	88
197	Detecting the Coronavirus (COVID-19). <i>ACS Sensors</i> , 2020, 5, 2283-2296.	7.8	196
198	Response of ophthalmologists in Israel to the novel coronavirus (2019-nCoV) outbreak. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2020, 258, 1419-1426.	1.9	5
199	Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19. <i>Bioengineering and Translational Medicine</i> , 2020, 5, e10163.	7.1	7
200	The Role of Antibody Testing for SARS-CoV-2: Is There One?. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	282

#	ARTICLE	IF	CITATIONS
201	The serostatus approach to fighting COVID-19. International Journal of Infectious Diseases, 2020, 94, 53-54.	3.3	3
202	ISIDOG Recommendations Concerning COVID-19 and Pregnancy. Diagnostics, 2020, 10, 243.	2.6	71
203	The important role of serology for COVID-19 control. Lancet Infectious Diseases, The, 2020, 20, 758-759.	9.1	201
204	SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell, 2020, 181, 1016-1035.e19.	28.9	1,956
205	COVID-19 pandemicâ€”a focused review for clinicians. Clinical Microbiology and Infection, 2020, 26, 842-847.	6.0	289
206	Seroconversion in household members of COVID-19 outpatients. Lancet Infectious Diseases, The, 2021, 21, 168.	9.1	11
207	Guidance for the procurement of COVIDâ€”19 convalescent plasma: differences between highâ€”and lowâ€”middleâ€”income countries. Vox Sanguinis, 2021, 116, 18-35.	1.5	48
208	Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. Cellular and Molecular Life Sciences, 2021, 78, 1501-1522.	5.4	95
209	Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for Patients With COVID-19â€”Nashville, Tennessee. Clinical Infectious Diseases, 2021, 72, 1645-1648.	5.8	104
210	Multisystem inflammatory syndrome in children related to COVIDâ€”19: A New York City experience. Journal of Medical Virology, 2021, 93, 424-433.	5.0	135
211	Development and clinical application of a rapid SARSâ€”CoVâ€”2 antibody test strip: A multiâ€”center assessment across China. Journal of Clinical Laboratory Analysis, 2021, 35, e23619.	2.1	10
212	Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nature Immunology, 2021, 22, 25-31.	14.5	403
213	Longitudinal Echocardiographic Assessment of Coronary Arteries and Left Ventricular Function following Multisystem Inflammatory Syndrome in Children. Journal of Pediatrics, 2021, 228, 290-293.e1.	1.8	37
214	Dupilumab, severe asthma airway responses, and SARSâ€”CoVâ€”2 serology. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 957-958.	5.7	26
215	Magnitude and Kinetics of Antiâ€”Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. Clinical Infectious Diseases, 2021, 72, 301-308.	5.8	175
216	Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform. Biosensors and Bioelectronics, 2021, 171, 112679.	10.1	89
217	Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples. American Journal of Clinical Pathology, 2021, 155, 267-279.	0.7	37
218	COVID-19: Discovery, diagnostics and drug development. Journal of Hepatology, 2021, 74, 168-184.	3.7	302

#	ARTICLE	IF	CITATIONS
219	Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 490-493.e2.	3.8	72
220	A critical review of point-of-care diagnostic technologies to combat viral pandemics. <i>Analytica Chimica Acta</i> , 2021, 1146, 184-199.	5.4	44
221	A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. <i>Journal of Infectious Diseases</i> , 2021, 223, 10-14.	4.0	21
222	Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. <i>Nature Microbiology</i> , 2021, 6, 51-58.	13.3	113
223	Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 223, 197-205.	4.0	216
224	Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12998.	2.7	201
225	Highly Sensitive and Specific Multiplex Antibody Assays To Quantify Immunoglobulins M, A, and G against SARS-CoV-2 Antigens. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	64
226	Clinical performance evaluation of a SARS-CoV-2 Rapid Antibody Test for determining past exposure to SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 103, 636-641.	3.3	11
227	Comparison of SARS-CoV-2 serological tests with different antigen targets. <i>Journal of Clinical Virology</i> , 2021, 134, 104690.	3.1	65
228	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. <i>Cell</i> , 2021, 184, 169-183.e17.	28.9	580
229	SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2021, 223, 589-599.	4.0	31
230	Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay. <i>Journal of Virological Methods</i> , 2021, 288, 114025.	2.1	94
231	Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19). <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 669-673.	1.3	45
232	SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. <i>Journal of Infectious Diseases</i> , 2021, 223, 62-71.	4.0	55
233	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. <i>Science</i> , 2021, 371, 79-82.	12.6	247
234	Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 864-868.	1.3	21
235	A high-throughput multiplexed microfluidic device for COVID-19 serology assays. <i>Lab on A Chip</i> , 2021, 21, 93-104.	6.0	53
236	A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. <i>Med</i> , 2021, 2, 149-163.e4.	4.4	85

#	ARTICLE	IF	CITATIONS
237	Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. Journal of Clinical Microbiology, 2021, 59, .	3.9	102
238	Nanozyme chemiluminescence paper test for rapid and sensitive detection of SARS-CoV-2 antigen. Biosensors and Bioelectronics, 2021, 173, 112817.	10.1	195
239	The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition. Journal of Molecular Biology, 2021, 433, 166748.	4.2	12
240	Emerging biosensing technologies for improved diagnostics of COVID-19 and future pandemics. Talanta, 2021, 225, 121986.	5.5	43
241	Enhanced SARS-CoV-2 neutralization by dimeric IgA. Science Translational Medicine, 2021, 13, .	12.4	379
242	Single-step, wash-free digital immunoassay for rapid quantitative analysis of serological antibody against SARS-CoV-2 by photonic resonator absorption microscopy. Talanta, 2021, 225, 122004.	5.5	43
243	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	30.7	265
244	Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature, 2021, 590, 146-150.	27.8	128
245	The potential application of electrochemical biosensors in the COVID-19 pandemic: A perspective on the rapid diagnostics of SARS-CoV-2. Biosensors and Bioelectronics, 2021, 176, 112905.	10.1	109
246	Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Annals of Clinical Biochemistry, 2021, 58, 123-131.	1.6	31
247	Technical considerations to development of serological tests for SARS-CoV-2. Talanta, 2021, 224, 121883.	5.5	27
248	Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages. Talanta, 2021, 225, 121898.	5.5	43
249	Molecular epidemiology in the HIV and SARS-CoV-2 pandemics. Current Opinion in HIV and AIDS, 2021, 16, 11-24.	3.8	5
250	Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG and IgM antibody rapid tests points to IgM as the Achilles heel. Journal of Medical Virology, 2021, 93, 2196-2203.	5.0	12
251	The scientific and ethical feasibility of immunity passports. Lancet Infectious Diseases, The, 2021, 21, e58-e63.	9.1	82
252	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 223, 56-61.	4.0	65
253	Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. Transfusion, 2021, 61, 78-93.	1.6	17
254	Neutralizing Antibody Responses in COVID-19 Convalescent Sera. Journal of Infectious Diseases, 2021, 223, 47-55.	4.0	70

#	ARTICLE	IF	CITATIONS
255	Evaluation of the Truvian Easy Check COVID-19 IgM/IgG Lateral Flow Device for Rapid Anti-SARS-CoV-2 Antibody Detection. American Journal of Clinical Pathology, 2021, 155, 286-295.	0.7	11
256	Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. Biotechnology and Bioengineering, 2021, 118, 1013-1021.	3.3	33
257	Infection with SARS-CoV-2 in primary care health care workers assessed by antibody testing. Family Practice, 2021, 38, 76-79.	1.9	25
258	A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization. Infection, 2021, 49, 75-82.	4.7	118
259	Antibody response and the clinical presentation of patients with COVID-19 in Croatia: the importance of a two-step testing approach. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 261-268.	2.9	12
260	N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2. Journal of Medical Virology, 2021, 93, 1732-1738.	5.0	12
261	Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial. Clinical Infectious Diseases, 2021, 72, e545-e551.	5.8	34
262	Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?. Clinical Infectious Diseases, 2021, 72, 1467-1474.	5.8	185
263	Use of convalescent plasma for COVID-19 in India: A review & practical guidelines. Indian Journal of Medical Research, 2021, 153, 64.	1.0	5
264	Study Protocol for DeCOMPRESS: Defining the Disease Course and Immune Profile of COVID-19 in the Immunosuppressed Patient. HRB Open Research, 0, 4, 6.	0.6	0
265	Vaccines™ Safety and Effectiveness in the Midst of Covid-19 Mutations. Health, 2021, 13, 283-298.	0.3	1
266	Prevalence of asymptomatic SARS-CoV-2 infection in elective surgical patients in Australia: a prospective surveillance study. ANZ Journal of Surgery, 2021, 91, 27-32.	0.7	8
267	Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals. Frontiers in Microbiology, 2020, 11, 618097.	3.5	30
268	ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. Vox Sanguinis, 2021, 116, 766-773.	1.5	22
270	Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virology Journal, 2021, 18, 16.	3.4	57
272	Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19). Clinical Transplantation, 2021, 35, e14221.	1.6	21
273	Magnetic Bead-Based Immunoassay Allows Rapid, Inexpensive, and Quantitative Detection of Human SARS-CoV-2 Antibodies. ACS Sensors, 2021, 6, 703-708.	7.8	61
274	Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. Clinical and Translational Immunology, 2021, 10, e1319.	3.8	34

#	ARTICLE	IF	CITATIONS
275	Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. <i>Emerging Microbes and Infections</i> , 2021, 10, 774-781.	6.5	38
276	Differential serological and neutralizing antibody dynamics after an infection by a single SARS-CoV-2 strain. <i>Infection</i> , 2021, 49, 781-783.	4.7	6
277	Capillary electrophoresis of glycoproteins. , 2021, , 645-727.		1
278	Epidemiology of COVID-19 in Misrata, Libya: A Population-Based Surveillance Study. <i>Open Journal of Epidemiology</i> , 2021, 11, 101-112.	0.4	2
279	Quantitative Measurement of IgG to Severe Acute Respiratory Syndrome Coronavirus-2 Proteins Using ImmunoCAP. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 417-424.	2.1	13
282	A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. <i>Cellular and Molecular Immunology</i> , 2021, 18, 318-327.	10.5	270
283	SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. <i>MBio</i> , 2021, 12, .	4.1	81
284	COVID-19 myocarditis and postinfection Bell's palsy. <i>BMJ Case Reports</i> , 2021, 14, e240095.	0.5	23
285	Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms (SNPs) analysis. <i>Virulence</i> , 2021, 12, 1209-1226.	4.4	16
286	Charting elimination in the pandemic: a SARS-CoV-2 serosurvey of blood donors in New Zealand. <i>Epidemiology and Infection</i> , 2021, 149, e173.	2.1	8
288	An overview of current COVID-19 vaccine platforms. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 2508-2517.	4.1	99
289	Persistence of SARS-CoV-2-specific IgG in Children 6 Months After Infection, Australia. <i>Emerging Infectious Diseases</i> , 2021, 27, 2233-2235.	4.3	13
290	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. <i>ACS Central Science</i> , 2021, 7, 183-199.	11.3	134
291	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	27.8	1,355
292	Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants. <i>Glycobiology</i> , 2022, 32, 60-72.	2.5	16
293	Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2. <i>Clinical and Translational Immunology</i> , 2021, 10, e1260.	3.8	13
294	Antibody response to SARS-CoV-2 in infected patients with different clinical outcome. <i>Journal of Medical Virology</i> , 2021, 93, 2548-2552.	5.0	12
295	Serological assays and host antibody detection in coronavirus-related disease diagnosis. <i>Archives of Virology</i> , 2021, 166, 715-731.	2.1	15

#	ARTICLE	IF	CITATIONS
296	A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2. <i>Viruses</i> , 2021, 13, 143.	3.3	16
297	Vision-Based Human Detection Techniques: A Descriptive Review. <i>IEEE Access</i> , 2021, 9, 42724-42761.	4.2	12
298	A comprehensive review on current COVID-19 detection methods: From lab care to point of care diagnosis. <i>Sensors International</i> , 2021, 2, 100119.	8.4	41
299	Cross-validation of ELISA and a portable surface plasmon resonance instrument for IgG antibody serology with SARS-CoV-2 positive individuals. <i>Analyst</i> , The, 2021, 146, 4905-4917.	3.5	28
300	Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. <i>Emerging Microbes and Infections</i> , 2021, 10, 664-676.	6.5	69
301	Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
302	Jobs, Housing, and Mask Wearing: Cross-Sectional Study of Risk Factors for COVID-19. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24320.	2.6	20
303	Optimized Recombinant Production of Secreted Proteins Using Human Embryonic Kidney (HEK293) Cells Grown in Suspension. <i>Bio-protocol</i> , 2021, 11, e3998.	0.4	14
304	A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses. <i>Nature Communications</i> , 2021, 12, 542.	12.8	200
305	Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. <i>PLoS Pathogens</i> , 2021, 17, e1009161.	4.7	62
307	Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. <i>Clinical and Translational Immunology</i> , 2021, 10, e1258.	3.8	28
308	'One Year Later' - SARS-CoV-2-Specific Immunity in Mild Cases of COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
309	High prevalence of anti-SARS-CoV-2 IgG antibody in the Xikrin of Bacajã (Kayapã) indigenous population in the Brazilian Amazon. <i>International Journal for Equity in Health</i> , 2021, 20, 50.	3.5	20
311	Immune dysregulation and system pathology in COVID-19. <i>Virulence</i> , 2021, 12, 918-936.	4.4	74
312	Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. <i>Cell Reports Medicine</i> , 2021, 2, 100189.	6.5	149
315	Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 2363.	0.9	5
317	Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	2.2	3
318	Humoral immunological kinetics of severe acute respiratory syndrome coronavirus 2 infection and diagnostic performance of serological assays for coronavirus disease 2019: an analysis of global reports. <i>International Health</i> , 2022, 14, 18-52.	2.0	11

#	ARTICLE	IF	CITATIONS
319	Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 90.	0.8	6
320	The use of dried blood spots for the serological evaluation of SARS-CoV-2 antibodies. <i>Journal of Public Health</i> , 2022, 44, e260-e263.	1.8	18
321	Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19. <i>Cell Reports Medicine</i> , 2021, 2, 100193.	6.5	37
322	Prevalence of SARS-CoV-2 Infection in Children by Antibody Detection in Saliva: Protocol for a Prospective Longitudinal Study (Coro-Buddy). <i>JMIR Research Protocols</i> , 2021, 10, e27739.	1.0	1
323	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 257-275.e6.	16.8	93
324	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. <i>Science</i> , 2021, 371, .	12.6	2,268
326	COVID-19 antibody screening with SARS-CoV-2 red cell kodecytes using routine serologic diagnostic platforms. <i>Transfusion</i> , 2021, 61, 1171-1180.	1.6	13
328	Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library. <i>Protein Science</i> , 2021, 30, 716-727.	7.6	16
329	Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1063-1071.	2.9	50
330	COVID-19 Antibody Tests and Their Limitations. <i>ACS Sensors</i> , 2021, 6, 593-612.	7.8	150
331	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. <i>Nature Communications</i> , 2021, 12, 1260.	12.8	115
332	Comparison of diagnostic accuracy for eight SARS-CoV-2 serological assays. <i>Biochemia Medica</i> , 2021, 31, 121-133.	2.7	9
333	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. <i>Nature Communications</i> , 2021, 12, 1152.	12.8	71
334	COVID-19 illness and autoimmune diseases: recent insights. <i>Inflammation Research</i> , 2021, 70, 407-428.	4.0	13
336	Establishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab061.	0.9	8
341	High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EE1A1-based plasmid vector. <i>PLoS ONE</i> , 2021, 16, e0242890.	2.5	24
342	Quantifying asymptomatic infection and transmission of COVID-19 in New York City using observed cases, serology, and testing capacity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	196
343	Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. <i>Clinical Microbiology Newsletter</i> , 2021, 43, 23-32.	0.7	29

#	ARTICLE	IF	CITATIONS
344	Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. PLoS Pathogens, 2021, 17, e1009165.	4.7	40
345	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature Communications, 2021, 12, 1162.	12.8	316
346	COVID-19 immune signatures reveal stable antiviral T <sub>H</sub> cell function despite declining humoral responses. Immunity, 2021, 54, 340-354.e6.	14.3	177
347	COVID-19 vaccine candidates: A review. Postepy Higieny I Medycyny Doswiadczalnej, 2021, 75, 58-63.	0.1	1
348	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. PLoS Pathogens, 2021, 17, e1009282.	4.7	42
350	A serological assay to detect human SARS-CoV-2 antibodies. Journal of Taibah University Medical Sciences, 2021, 16, 57-62.	0.9	12
351	COVID-19 mRNA vaccines. Journal of Genetics and Genomics, 2021, 48, 107-114.	3.9	59
352	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	27.8	1,232
355	Serological Test to Determine Exposure to SARS-CoV-2: ELISA Based on the Receptor-Binding Domain of the Spike Protein (S-RBDN318-V510) Expressed in Escherichia coli. Diagnostics, 2021, 11, 271.	2.6	17
356	SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population. Cell Reports Medicine, 2021, 2, 100191.	6.5	32
359	Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine, 2021, 32, 100734.	7.1	134
360	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature Communications, 2021, 12, 1018.	12.8	82
361	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines, 2021, 9, 171.	4.4	43
365	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. Scientific Reports, 2021, 11, 4290.	3.3	22
366	Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera. MBio, 2021, 12, .	4.1	64
367	Optical Detection of CoV-SARS-2 Viral Proteins to Sub-Picomolar Concentrations. ACS Omega, 2021, 6, 6404-6413.	3.5	38
368	Adaptive immunity to SARS-CoV-2 and COVID-19. Cell, 2021, 184, 861-880.	28.9	1,364
369	SARS-CoV-2 virus: Vaccines in development. Fundamental Research, 2021, 1, 131-138.	3.3	12

#	ARTICLE	IF	CITATIONS
372	SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 629185.	4.8	42
373	Diagnostic Value of IgM and IgG Detection in COVID-19 Diagnosis by the Mobile Laboratory B-LiFE: A Massive Testing Strategy in the Piedmont Region. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3372.	2.6	3
374	The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. <i>Blood Advances</i> , 2021, 5, 1305-1309.	5.2	83
376	Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines. <i>Microorganisms</i> , 2021, 9, 683.	3.6	25
377	What do we know about the antibody responses to SARS-CoV-2?. <i>Immunobiology</i> , 2021, 226, 152054.	1.9	23
378	A homogeneous split-luciferase assay for rapid and sensitive detection of anti-SARS CoV-2 antibodies. <i>Nature Communications</i> , 2021, 12, 1806.	12.8	36
381	Multiplex bead binding assays using off-the-shelf components and common flow cytometers. <i>Journal of Immunological Methods</i> , 2021, 490, 112952.	1.4	10
382	Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses. <i>F1000Research</i> , 2021, 10, 196.	1.6	7
383	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. <i>Biology</i> , 2021, 10, 208.	2.8	16
386	Ultrasensitive Measurement of Both SARS-CoV-2 RNA and Antibodies from Saliva. <i>Analytical Chemistry</i> , 2021, 93, 5365-5370.	6.5	34
387	COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors. <i>Transfusion</i> , 2021, 61, 1471-1478.	1.6	9
389	Real-time measurement of the uncertain epidemiological appearances of COVID-19 infections. <i>Applied Soft Computing Journal</i> , 2021, 101, 107039.	7.2	33
390	Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike. <i>ACS Central Science</i> , 2021, 7, 586-593.	11.3	68
391	Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. <i>Nature Immunology</i> , 2021, 22, 620-626.	14.5	320
392	Risk and Assessment of COVID-19 in a Retina Ophthalmologic Setting. , 0, , 1-6.		0
396	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100208.	6.5	115
397	COVID-19 Pandemic: Review of Contemporary and Forthcoming Detection Tools. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1049-1082.	2.7	37
398	Diagnosis for COVID-19: current status and future prospects. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 269-288.	3.1	29

#	ARTICLE	IF	CITATIONS
399	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. PLoS ONE, 2021, 16, e0248348.	2.5	102
400	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. Nature Communications, 2021, 12, 1951.	12.8	54
401	Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. Scientific Reports, 2021, 11, 6614.	3.3	33
402	Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med, 2021, 2, 281-295.e4.	4.4	153
403	A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies. Scientific Reports, 2021, 11, 5198.	3.3	55
404	Case Study: Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. , 2021, , .		3
406	Multiplexed Serum Antibody Screening Platform Using Virus Extracts from Endemic <i>Coronaviridae</i> and SARS-CoV-2. ACS Infectious Diseases, 2021, 7, 1596-1606.	3.8	7
408	Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series. Life, 2021, 11, 247.	2.4	8
409	SARS-CoV-2 seroconversion among 4040 Egyptian healthcare workers in 12 resource-limited healthcare facilities: A prospective cohort study. International Journal of Infectious Diseases, 2021, 104, 534-542.	3.3	16
410	SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital â€” New York City, April 2020. Morbidity and Mortality Weekly Report, 2021, 70, 308-311.	15.1	18
411	SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients. Frontiers in Plant Science, 2021, 12, 589940.	3.6	31
412	Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection. EBioMedicine, 2021, 65, 103259.	6.1	61
413	Features of developing SARS-CoV-2 nucleocapsid protein population-based seroprevalence during the first wave of the COVID-19 epidemic in the Russian Federation. Russian Journal of Infection and Immunity, 2021, 11, 297-323.	0.7	30
414	Chest pain mimicking pulmonary embolism may be a common presentation of COVID-19 in ambulant patients without other typical features of infection. Journal of Internal Medicine, 2021, 290, 349-358.	6.0	6
415	COVID-19 convalescent plasma; time for â€œgoal directed therapyâ€?. Transfusion, 2021, 61, 1654-1656.	1.6	2
416	Severe Acute Respiratory Syndrome Coronavirus 2 Viral RNA Load Status and Antibody Distribution Among Patients and Asymptomatic Carriers in Central China. Frontiers in Cellular and Infection Microbiology, 2021, 11, 559447.	3.9	2
420	Prevalence of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients. Immunological Investigations, 2022, 51, 993-1004.	2.0	8
421	Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection. Nature Biotechnology, 2021, 39, 928-935.	17.5	106

#	ARTICLE	IF	CITATIONS
422	A study on the effects of containment policies and vaccination on the spread of SARS-CoV-2. PLoS ONE, 2021, 16, e0247439.	2.5	5
423	Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity, 2021, 54, 557-570.e5.	14.3	153
424	Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020. Frontiers in Cellular and Infection Microbiology, 2021, 11, 650487.	3.9	3
426	Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice. Journal of the American Heart Association, 2021, 10, e019506.	3.7	8
427	Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. Journal of Medical Virology, 2021, 93, 3211-3218.	5.0	52
428	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nature Communications, 2021, 12, 1403.	12.8	65
429	Production of high-quality SARS-CoV-2 antigens: Impact of bioprocess and storage on glycosylation, biophysical attributes, and ELISA serologic tests performance. Biotechnology and Bioengineering, 2021, 118, 2202-2219.	3.3	27
430	Immunodetection of Lung IgG and IgM Antibodies against SARS-CoV-2 via Enzymatic Liquefaction of Respiratory Samples from COVID-19 Patients. Analytical Chemistry, 2021, 93, 5259-5266.	6.5	8
431	Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities. Scientific Reports, 2021, 11, 5538.	3.3	37
432	COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice. Journal of Virology, 2021, 95, .	3.4	78
434	Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitro. Frontiers in Immunology, 2021, 12, 613045.	4.8	14
435	N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. Nature Communications, 2021, 12, 1931.	12.8	104
438	Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. MSphere, 2021, 6, .	2.9	11
439	IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals. Nature Communications, 2021, 12, 2133.	12.8	44
442	Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. Frontiers in Immunology, 2021, 12, 614676.	4.8	13
444	Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. Viruses, 2021, 13, 697.	3.3	36
445	A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	44
446	NeutrobodyPlex monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. EMBO Reports, 2021, 22, e52325.	4.5	43

#	ARTICLE	IF	CITATIONS
450	Paper-Based Biosensors: Frontiers in Point-of-Care Detection of COVID-19 Disease. Biosensors, 2021, 11, 110.	4.7	39
451	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	12.8	102
452	Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis. JMIR Public Health and Surveillance, 2021, 7, e25500.	2.6	19
455	Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. MBio, 2021, 12, .	4.1	62
456	Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. Cell Reports Medicine, 2021, 2, 100253.	6.5	40
458	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. Open Forum Infectious Diseases, 2021, 8, ofab220.	0.9	33
459	Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. Lancet Regional Health - Europe, The, 2021, 3, 100014.	5.6	39
460	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications, 2021, 12, 2037.	12.8	125
462	COVID-19 Diagnostic Strategies Part II: Protein-Based Technologies. Bioengineering, 2021, 8, 54.	3.5	14
463	Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell, 2021, 184, 1858-1864.e10.	28.9	332
464	A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics. Journal of Infectious Diseases, 2021, 224, 218-228.	4.0	25
465	Review of the Microbiological Diagnostic Approaches of COVID-19. Frontiers in Public Health, 2021, 9, 592500.	2.7	4
466	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. Heliyon, 2021, 7, e06836.	3.2	11
468	Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests. Journal of Virological Methods, 2021, 290, 114067.	2.1	18
469	Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals. Communications Biology, 2021, 4, 486.	4.4	15
470	Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course. Clinical Biochemistry, 2021, 90, 1-7.	1.9	11
471	Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers. Scientific Reports, 2021, 11, 7614.	3.3	26
473	An international comparison of anti-SARS-CoV-2 assays used for seroprevalence surveys from blood component providers. Vox Sanguinis, 2021, 116, 946-954.	1.5	6

#	ARTICLE	IF	CITATIONS
475	Serological Tests in the Detection of SARS-CoV-2 Antibodies. <i>Diagnostics</i> , 2021, 11, 678.	2.6	9
477	A Low-Cost SARS-CoV-2 rRBD ELISA to Detect Serostatus in Ecuadorian Population with COVID-19. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1513-1515.	1.4	5
478	Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan. <i>Journal of Medical Microbiology</i> , 2021, 70, .	1.8	4
479	Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. <i>Viral Immunology</i> , 2021, 34, 201-209.	1.3	31
480	Role of rapid antibody and ELISA tests in the evaluation of serological response in patients with SARS-CoV-2 PCR positivity. <i>Folia Microbiologica</i> , 2021, 66, 579-586.	2.3	3
483	Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	30
484	Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies. <i>Viruses</i> , 2021, 13, 713.	3.3	18
485	Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1444-1452.	2.3	46
486	Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay. <i>International Journal of Infectious Diseases</i> , 2021, 105, 21-25.	3.3	43
487	Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow Immunoassay. <i>ACS Nano</i> , 2021, 15, 8996-9004.	14.6	109
488	Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya. <i>Clinical Infectious Diseases</i> , 2022, 74, 288-293.	5.8	36
489	IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4951.	4.1	20
491	Parameters of immunoglobulin extraction from dried blood spot cards and immunoassays for detection of antibody response to pathogens including the novel SARS-CoV-2. <i>Journal of Immunological Methods</i> , 2021, 492, 112996.	1.4	1
493	Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B.1.351 Isolates in Microneutralization Assays. <i>Viruses</i> , 2021, 13, 996.	3.3	14
494	A Generic, Scalable, and Rapid Time-Resolved Förster Resonance Energy Transfer-Based Assay for Antigen Detection of SARS-CoV-2 as a Proof of Concept. <i>MBio</i> , 2021, 12, .	4.1	40
495	Electrochemical diagnostics of infectious viral diseases: Trends and challenges. <i>Biosensors and Bioelectronics</i> , 2021, 180, 113112.	10.1	63
496	Conserved and Novel Mouse CD8 T Cell Epitopes within SARS-CoV-2 Spike Receptor Binding Domain Protein Identified following Subunit Vaccination. <i>Journal of Immunology</i> , 2021, 206, 2503-2507.	0.8	11
497	Facile Determination of COVID-19 Seroconversion via Nonradiative Energy Transfer. <i>ACS Sensors</i> , 2021, 6, 2136-2140.	7.8	5

#	ARTICLE	IF	CITATIONS
498	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. <i>Cell</i> , 2021, 184, 2618-2632.e17.	28.9	80
499	Vaccination strategy and anti - SARS-CoV-2 titers in healthcare workers of the INT “ IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy). <i>Infectious Agents and Cancer</i> , 2021, 16, 32.	2.6	15
500	Capacidad de respuesta inmunitaria al COVID-19 en pacientes en hemodiálisis. <i>Revista De Investigación Y Educación En Ciencias De La Salud (RIECS)</i> , 2021, 6, 75-81.	0.0	0
504	Adaptive immune responses to SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 1-8.	13.7	6
508	Comparative Analysis of Antigen-Specific Anti“SARS-CoV-2 Antibody Isotypes in COVID-19 Patients. <i>Journal of Immunology</i> , 2021, 206, 2393-2401.	0.8	19
509	A simple, sensitive, and low-cost FACS assay for detecting antibodies against the native SARS-CoV-2 spike protein. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 905-917.	2.7	5
510	New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. <i>Archives of Disease in Childhood</i> , 2022, 107, 180-185.	1.9	91
511	Testing at scale during the COVID-19 pandemic. <i>Nature Reviews Genetics</i> , 2021, 22, 415-426.	16.3	261
512	Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. <i>Cell Reports Medicine</i> , 2021, 2, 100288.	6.5	121
513	Multichannel Immunosensor Platform for the Rapid Detection of SARS-CoV-2 and Influenza A(H1N1) Virus. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 22262-22270.	8.0	41
515	Dynamics of anti-SARS-CoV-2 IgG antibodies post-COVID-19 in a Brazilian Amazon population. <i>BMC Infectious Diseases</i> , 2021, 21, 443.	2.9	16
516	Different Laboratory Diagnosis Methods of COVID-19: A Systematic Review. <i>Archives of Clinical Infectious Diseases</i> , 2021, 16, .	0.2	6
518	DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist. <i>PLoS Pathogens</i> , 2021, 17, e1009576.	4.7	133
519	CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. <i>Immunity</i> , 2021, 54, 1066-1082.e5.	14.3	106
521	Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. <i>Thrombosis Research</i> , 2021, 201, 100-112.	1.7	42
524	Antibodies: what makes us stronger. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3551-3553.	3.3	1
525	A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests. <i>EBioMedicine</i> , 2021, 67, 103348.	6.1	34
526	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. <i>Nature Communications</i> , 2021, 12, 2670.	12.8	297

#	ARTICLE	IF	CITATIONS
527	Delayed production of neutralizing antibodies correlates with fatal COVID-19. <i>Nature Medicine</i> , 2021, 27, 1178-1186.	30.7	183
529	Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors. <i>Frontiers in Microbiology</i> , 2021, 12, 661187.	3.5	21
530	Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. <i>Journal of Infectious Diseases</i> , 2021, 224, 407-414.	4.0	43
531	COVID-19 serological survey using micro blood sampling. <i>Scientific Reports</i> , 2021, 11, 9475.	3.3	12
534	Prevalence and Clinical Profile of Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Farmworkers, California, USA, June–November 2020. <i>Emerging Infectious Diseases</i> , 2021, 27, 1330-1342.	4.3	23
536	Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens. <i>Human Antibodies</i> , 2021, 29, 109-113.	1.5	7
537	Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure. <i>JCI Insight</i> , 2021, 6, .	5.0	24
538	Flow cytometry detection of sustained humoral immune response (IgG+IgA) against native spike glycoprotein in asymptomatic/mild SARS-CoV-2 infection. <i>Scientific Reports</i> , 2021, 11, 10716.	3.3	3
544	Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay. <i>Diagnostics</i> , 2021, 11, 994.	2.6	17
545	A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): A consensus of Latin American experts. <i>International Journal of Infectious Diseases</i> , 2021, , .	3.3	0
548	Development of a high-sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS-CoV-2 spike glycoprotein in serum and saliva. <i>Immunology</i> , 2021, 164, 135-147.	4.4	35
549	Multiplexed, microscale, microarray-based serological assay for antibodies against all human-relevant coronaviruses. <i>Journal of Virological Methods</i> , 2021, 291, 114111.	2.1	11
550	International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses. <i>Vox Sanguinis</i> , 2021, 116, e71-e120.	1.5	3
551	Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. <i>Nature Communications</i> , 2021, 12, 3109.	12.8	118
552	Durability of the humoral immune response in recovered COVID-19 patients. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 2802-2806.	3.8	11
553	Diverse functional autoantibodies in patients with COVID-19. <i>Nature</i> , 2021, 595, 283-288.	27.8	619
554	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1339-1344.	0.9	202
555	Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform. <i>PLoS ONE</i> , 2021, 16, e0252628.	2.5	11

#	ARTICLE	IF	CITATIONS
556	Machine learning and computation-enabled intelligent sensor design. <i>Nature Machine Intelligence</i> , 2021, 3, 556-565.	16.0	86
558	COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men. <i>Journal of Infectious Diseases</i> , 2021, 224, 793-797.	4.0	30
560	Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation. <i>Gene Reports</i> , 2021, 23, 101140.	0.8	13
561	Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 886-891.	6.0	51
562	Immunological imprinting of the antibody response in COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 3781.	12.8	149
563	Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab314.	0.9	12
564	Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	1.4	9
565	Rapid and accurate agglutination-based testing for SARS-CoV-2 antibodies. <i>Cell Reports Methods</i> , 2021, 1, 100011.	2.9	11
566	An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. <i>ACS Central Science</i> , 2021, 7, 1191-1204.	11.3	34
567	Titers, Prevalence, and Duration of SARS-CoV-2 Antibodies in a Local COVID-19 Outbreak and Following Vaccination. <i>Vaccines</i> , 2021, 9, 587.	4.4	6
568	SARS-CoV-2 Peptide Bioconjugates Designed for Antibody Diagnostics. <i>Bioconjugate Chemistry</i> , 2021, 32, 1606-1616.	3.6	7
569	A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. <i>Viruses</i> , 2021, 13, 1055.	3.3	4
570	Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. <i>Scientific Reports</i> , 2021, 11, 13308.	3.3	50
571	Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	13.6	205
572	Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients. <i>IScience</i> , 2021, 24, 102489.	4.1	11
573	Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry. <i>Scientific Reports</i> , 2021, 11, 12448.	3.3	22
574	A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. <i>Pathogens</i> , 2021, 10, 710.	2.8	8
576	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. <i>ACS Nano</i> , 2021, 15, 11180-11191.	14.6	60

#	ARTICLE	IF	CITATIONS
578	N-Glycosylation of the SARS-CoV-2 Receptor Binding Domain Is Important for Functional Expression in Plants. <i>Frontiers in Plant Science</i> , 2021, 12, 689104.	3.6	34
579	Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. <i>Nature Communications</i> , 2021, 12, 3966.	12.8	40
580	The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe. <i>Covid</i> , 2021, 1, 20-38.	1.5	22
581	Diagnostic and analytical performance evaluation of ten commercial assays for detecting SARS-CoV-2 humoral immune response. <i>Journal of Immunological Methods</i> , 2021, 493, 113043.	1.4	10
582	Persisting Antibody Response to SARS-CoV-2 in a Local Austrian Population. <i>Frontiers in Medicine</i> , 2021, 8, 653630.	2.6	8
584	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. <i>Immunity</i> , 2021, 54, 1290-1303.e7.	14.3	101
585	Multiplex quantitative detection of SARS-CoV-2 specific IgG and IgM antibodies based on DNA-assisted nanopore sensing. <i>Biosensors and Bioelectronics</i> , 2021, 181, 113134.	10.1	43
586	A comparative review of immunoassays for COVID-19 detection. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 573-599.	3.0	74
587	Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 3695.	12.8	32
589	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021, 10, 1412.	4.1	6
591	Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test. <i>Science Advances</i> , 2021, 7, .	10.3	42
592	Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2. <i>ACS Central Science</i> , 2021, 7, 1009-1018.	11.3	113
593	Human IgG and IgA responses to COVID-19 mRNA vaccines. <i>PLoS ONE</i> , 2021, 16, e0249499.	2.5	148
594	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	27.8	610
595	High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay. <i>Scientific Reports</i> , 2021, 11, 12330.	3.3	12
596	Green chemistry and coronavirus. <i>Sustainable Chemistry and Pharmacy</i> , 2021, 21, 100415.	3.3	29
598	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	12.8	241
599	A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0019321.	3.9	20

#	ARTICLE	IF	CITATIONS
600	Young infants exhibit robust functional antibody responses and restrained IFN- $\gamma$ production to SARS-CoV-2. <i>Cell Reports Medicine</i> , 2021, 2, 100327.	6.5	29
601	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	27.8	154
602	Long COVID in a prospective cohort of home-isolated patients. <i>Nature Medicine</i> , 2021, 27, 1607-1613.	30.7	453
603	Unified platform for genetic and serological detection of COVID-19 with single-molecule technology. <i>PLoS ONE</i> , 2021, 16, e0255096.	2.5	5
608	Current vaccine technology with an emphasis on recombinant measles virus as a new perspective for vaccination against SARS-CoV-2. <i>Euro-Mediterranean Journal for Environmental Integration</i> , 2021, 6, 61.	1.3	0
609	SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain. <i>Journal of Immunology</i> , 2021, 207, 878-887.	0.8	30
611	Development of rapid and cost-effective top-loading device for the detection of anti-SARS-CoV-2 IgG/IgM antibodies. <i>Scientific Reports</i> , 2021, 11, 14926.	3.3	1
612	Cohabitation With a Known Coronavirus Disease 2019 Case Is Associated With Greater Antibody Concentration and Symptom Severity in a Community-Based Sample of Seropositive Adults. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab244.	0.9	6
614	Epitope-specific antibody responses differentiate COVID-19 outcomes and variants of concern. <i>JCI Insight</i> , 2021, 6, .	5.0	32
615	Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing. <i>Translational Medicine Communications</i> , 2021, 6, 13.	1.4	1
617	Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021, 16, e0253977.	2.5	35
618	Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study. <i>Microorganisms</i> , 2021, 9, 1643.	3.6	19
619	Expression of SARS-CoV-2 surface glycoprotein fragment 319-640 in <i>E. coli</i> , and its refolding and purification. <i>Protein Expression and Purification</i> , 2021, 183, 105861.	1.3	25
620	Performance of Three SARS-CoV-2 Immunoassays, Three Rapid Lateral Flow Tests, and a Novel Bead-Based Affinity Surrogate Test for the Detection of SARS-CoV-2 Antibodies in Human Serum. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0031921.	3.9	10
621	Enhancing the Stability of COVID-19 Serological Assay through Metal-Organic Framework Encapsulation. <i>Advanced Healthcare Materials</i> , 2021, 10, 2100410.	7.6	4
623	Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. <i>Viruses</i> , 2021, 13, 1371.	3.3	11
624	SARS-CoV2 IgG antibody: Seroprevalence among health care workers. <i>Clinical Epidemiology and Global Health</i> , 2021, 11, 100766.	1.9	9
626	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. <i>PLoS ONE</i> , 2021, 16, e0254667.	2.5	4

#	ARTICLE	IF	CITATIONS
629	Immunological aspects of SARS-CoV-2 coronavirus damage. Vestnik of Russian Military Medical Academy, 2021, 23, 187-198.	0.3	9
631	High-resolution serum proteome trajectories in COVID-19 reveal patient-specific seroconversion. EMBO Molecular Medicine, 2021, 13, e14167.	6.9	92
632	Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses. PLoS ONE, 2021, 16, e0254367.	2.5	17
633	SARS-CoV-2 Receptor Binding Domain as a Stable-Potential Target for SARS-CoV-2 Detection by Surface-Enhanced Raman Spectroscopy. Sensors, 2021, 21, 4617.	3.8	15
635	Disease-dependent interaction policies to support health and economic outcomes during the COVID-19 epidemic. IScience, 2021, 24, 102710.	4.1	12
636	Assessment of serological assays for identifying high titer convalescent plasma. Transfusion, 2021, 61, 2658-2667.	1.6	7
638	Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. Science Advances, 2021, 7, .	10.3	60
639	Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Science Translational Medicine, 2021, 13, .	12.4	180
640	Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography. Frontiers in Immunology, 2021, 12, 696370.	4.8	14
641	Seroprevalence of SARS-CoV-2 antibodies in health-care workers at a tertiary paediatric hospital. Journal of Paediatrics and Child Health, 2021, 57, 1136-1139.	0.8	2
643	Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip. Mikrochimica Acta, 2021, 188, 262.	5.0	23
644	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Science Advances, 2021, 7, .	10.3	117
645	Contributions of the international plant science community to the fight against human infectious diseases – part 1: epidemic and pandemic diseases. Plant Biotechnology Journal, 2021, 19, 1901-1920.	8.3	44
646	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules, 2021, 11, 993.	4.0	136
648	Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in waters via surface enhanced Raman scattering (SERS). Water Research, 2021, 200, 117243.	11.3	77
649	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell, 2021, 184, 3936-3948.e10.	28.9	241
650	Coronavirus Disease 2019 (COVID-19) Diagnostic Tools: A Focus on Detection Technologies and Limitations. Current Issues in Molecular Biology, 2021, 43, 728-748.	2.4	26
651	Diverse high-affinity DNA aptamers for wild-type and B.1.1.7 SARS-CoV-2 spike proteins from a pre-structured DNA library. Nucleic Acids Research, 2021, 49, 7267-7279.	14.5	77

#	ARTICLE	IF	CITATIONS
653	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	12.8	88
656	Characterization of the Diagnostic Performance of a Novel COVID-19 PETIA in Comparison to Four Routine N-, S- and RBD-Antigen Based Immunoassays. <i>Diagnostics</i> , 2021, 11, 1332.	2.6	4
657	Humoral immune responses in hospitalized COVID-19 patients. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 4055-4061.	3.8	3
658	Luciferase-Based Biosensors in the Era of the COVID-19 Pandemic. <i>ACS Nanoscience Au</i> , 2021, 1, 15-37.	4.8	9
659	SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. <i>Nature Microbiology</i> , 2021, 6, 1188-1198.	13.3	314
660	SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes. <i>Microorganisms</i> , 2021, 9, 1744.	3.6	16
661	Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 723585.	4.8	11
662	Delayed neutralizing antibody response in the acute phase correlates with severe progression of COVID-19. <i>Scientific Reports</i> , 2021, 11, 16535.	3.3	12
663	Validation of high-throughput, semiquantitative solid-phase SARS-CoV-2 serology assays in serum and dried blood spot matrices. <i>Bioanalysis</i> , 2021, 13, 1183-1193.	1.5	7
664	Immunity to SARS-CoV-2 induced by infection or vaccination. <i>Journal of Internal Medicine</i> , 2022, 291, 32-50.	6.0	97
665	Associations of SARS-CoV-2 serum IgG with occupation and demographics of military personnel. <i>PLoS ONE</i> , 2021, 16, e0251114.	2.5	1
666	Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1862-1864.	1.9	19
667	COVID-19 clinical and laboratory diagnosis overview. <i>Journal of the Egyptian Public Health Association, The</i> , 2021, 96, 25.	2.5	7
669	Single-antigen multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients by flow cytometry. <i>European Journal of Immunology</i> , 2021, 51, 2633-2640.	2.9	9
671	Recent Advances in Novel Lateral Flow Technologies for Detection of COVID-19. <i>Biosensors</i> , 2021, 11, 295.	4.7	66
674	Longitudinal COVID-19 Surveillance and Characterization in the Workplace with Public Health and Diagnostic Endpoints. <i>MSphere</i> , 2021, 6, e0054221.	2.9	5
676	Recombinant Antigens Based on Non-Glycosylated Regions from RBD SARS-CoV-2 as Potential Vaccine Candidates against COVID-19. <i>Vaccines</i> , 2021, 9, 928.	4.4	12
679	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1028-1030.	16.8	176

#	ARTICLE	IF	CITATIONS
681	Significance of SARS-CoV-2 specific antibody testing during COVID-19 vaccine allocation. Vaccine, 2021, 39, 5055-5063.	3.8	21
682	Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. ELife, 2021, 10, .	6.0	267
683	Healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among Thai healthcare personnel who receive 2 doses of a coronavirus disease 2019 (COVID-19) vaccine: A call for considering a booster dose. Infection Control and Hospital Epidemiology, 2021, , 1-2.	1.8	4
686	SARS-CoV-2 RNA and antibody detection in breast milk from a prospective multicentre study in Spain. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2022, 107, 216-221.	2.8	33
687	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. Immunity, 2021, 54, 2385-2398.e10.	14.3	46
688	Clinical Spectrum of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Protection From Symptomatic Reinfection. Clinical Infectious Diseases, 2022, 75, e257-e266.	5.8	33
689	Combating the progression of novel coronavirus SARS-CoV-2 infectious Disease: Current state and future prospects in molecular diagnostic and drug discovery. Current Molecular Medicine, 2021, 21, .	1.3	6
690	Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clinica Chimica Acta, 2021, 519, 60-63.	1.1	74
692	SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic. Viruses, 2021, 13, 1648.	3.3	22
693	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. Science Immunology, 2021, 6, .	11.9	20
694	Serological surveys to estimate cumulative incidence of SARS-CoV-2 infection in adults (Sero-MAss) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.9	7
696	Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Reports, 2021, 36, 109518.	6.4	142
697	Mass spectrometry-based proteomics in basic and translational research of SARS-CoV-2 coronavirus and its emerging mutants. Clinical Proteomics, 2021, 18, 19.	2.1	12
698	B cells promote CD8 T cell primary and memory responses to subunit vaccines. Cell Reports, 2021, 36, 109591.	6.4	21
699	SARS-CoV-2 Antibody Testing: Where Are We Now?. Laboratory Medicine, 2021, , .	1.2	2
701	Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner. MBio, 2021, 12, e0100221.	4.1	7
702	The association between obesity and peak antibody titer response in COVID-19 infection. Obesity, 2021, 29, 1547-1553.	3.0	35
703	Evaluation of rapid antibody test and chest computed tomography results of COVID-19 patients: A retrospective study. Journal of Medical Virology, 2021, 93, 6582-6587.	5.0	5

#	ARTICLE	IF	CITATIONS
705	Development and Evaluation of a Set of Spike and Receptor Binding Domain-Based Enzyme-Linked Immunosorbent Assays for SARS-CoV-2 Serological Testing. <i>Diagnostics</i> , 2021, 11, 1506.	2.6	10
706	Structure of herd immunity to SARS-COV-2 in the Krasnoyarsk region population in the COVID-19 epidemic. <i>Acta Biomedica Scientifica</i> , 2021, 6, 227-238.	0.2	2
707	Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein. <i>MSphere</i> , 2021, 6, e0064721.	2.9	40
709	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. <i>Scientific Reports</i> , 2021, 11, 17325.	3.3	27
710	Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab420.	0.9	12
711	Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. <i>Human Pathology</i> , 2021, 114, 110-119.	2.0	32
712	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. <i>PLoS Pathogens</i> , 2021, 17, e1009772.	4.7	74
713	Seroprevalence of COVID-19 IgG antibodies among healthcare workers of Pakistan: a cross-sectional study assessing exposure to COVID-19 and identification of high-risk subgroups. <i>BMJ Open</i> , 2021, 11, e046276.	1.9	7
714	Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites. <i>EMBO Journal</i> , 2021, 40, e108375.	7.8	44
715	An Approach to Transitioning Undergraduate Biochemistry Laboratory Courses Online. <i>The Biophysicist</i> , 2021, 2, 33-37.	0.3	1
716	Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.. <i>EClinicalMedicine</i> , 2021, 38, 101018.	7.1	77
717	Household level SARS-CoV-2 sero-epidemiology in a high prevalence group of adults and children-implications for community infection control. <i>American Journal of Infection Control</i> , 2021, 49, 1438-1440.	2.3	0
718	A Linkage-specific Sialic Acid Labeling Strategy Reveals Different Site-specific Glycosylation Patterns in SARS-CoV-2 Spike Protein Produced in CHO and HEK Cell Substrates. <i>Frontiers in Chemistry</i> , 2021, 9, 735558.	3.6	12
719	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. <i>Scientific Reports</i> , 2021, 11, 17642.	3.3	41
721	Development of in-house, indirect ELISAs for the detection of SARS-CoV-2 spike protein-associated serology in COVID-19 patients in Panama. <i>PLoS ONE</i> , 2021, 16, e0257351.	2.5	6
722	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021, 54, 2159-2166.e6.	14.3	52
723	Impact of Specific N-Glycan Modifications on the Use of Plant-Produced SARS-CoV-2 Antigens in Serological Assays. <i>Frontiers in Plant Science</i> , 2021, 12, 747500.	3.6	8
724	Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera. <i>Microbiology Spectrum</i> , 2021, 9, e0045821.	3.0	3

#	ARTICLE	IF	CITATIONS
725	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. <i>Science Immunology</i> , 2021, 6, eabl4509.	11.9	141
726	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0052721.	3.9	71
727	Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients. <i>Viral Immunology</i> , 2021, 34, 708-713.	1.3	2
728	Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area. <i>Digestive and Liver Disease</i> , 2022, 54, 3-9.	0.9	8
730	SARS-CoV-2 seroprevalence and associated factors in Manaus, Brazil: baseline results from the DETECTCoV-19 cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 110, 141-150.	3.3	32
731	Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10253.	7.1	19
732	SARS-CoV-2 infection shortly after BNT162b2 vaccination results in high anti-spike antibody levels in nursing home residents and staff. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1702-1706.	2.7	15
733	The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 737083.	4.8	18
734	New-onset IgG autoantibodies in hospitalized patients with COVID-19. <i>Nature Communications</i> , 2021, 12, 5417.	12.8	286
735	Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. <i>Science</i> , 2021, 374, eabj9853.	12.6	236
736	SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans. <i>Frontiers in Immunology</i> , 2021, 12, 728021.	4.8	20
737	Differential pre-pandemic breast milk IgA reactivity against SARS-CoV-2 and circulating human coronaviruses in Ugandan and American mothers. <i>International Journal of Infectious Diseases</i> , 2021, 112, 165-172.	3.3	6
738	Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response. <i>Microbiology Spectrum</i> , 2021, 9, e0073321.	3.0	22
739	Recombinant Protein Expression and Purification of N, S1, and RBD of SARS-CoV-2 from Mammalian Cells and Their Potential Applications. <i>Diagnostics</i> , 2021, 11, 1808.	2.6	12
740	Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. <i>JAMA Network Open</i> , 2021, 4, e2123622.	5.9	49
741	SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. <i>Vaccine</i> , 2021, 39, 5769-5779.	3.8	23
744	SARS-CoV-2 integral membrane proteins shape the serological responses of patients with COVID-19. <i>Science</i> , 2021, 24, 103185.	4.1	13
745	The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein. <i>Royal Society Open Science</i> , 2021, 8, 211016.	2.4	19

#	ARTICLE	IF	CITATIONS
746	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. <i>Journal of Immunological Methods</i> , 2021, 499, 113160.	1.4	12
748	A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0118621.	3.9	6
749	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. <i>MBio</i> , 2021, 12, e0190821.	4.1	32
751	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. <i>Cell Reports</i> , 2021, 37, 109822.	6.4	35
752	Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. <i>JCI Insight</i> , 2021, 6, .	5.0	45
754	A rapid test recognizing mucosal SARS-CoV-2-specific antibodies distinguishes prodromal from convalescent COVID-19. <i>IScience</i> , 2021, 24, 103194.	4.1	1
755	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1261-1269.	3.9	84
756	Serological assessment of SARS-CoV-2 infection during the first wave of the pandemic in Louisville Kentucky. <i>Scientific Reports</i> , 2021, 11, 18285.	3.3	10
757	Seroprevalence of Immunoglobulin-G Antibody Among Confirm Cases of COVID-19. <i>Cureus</i> , 2021, 13, e17956.	0.5	1
758	Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors. <i>Science Advances</i> , 2021, 7, eabh2848.	10.3	87
759	Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. <i>IScience</i> , 2021, 24, 102937.	4.1	10
760	Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1481-1492.e2.	2.9	43
761	COVID-19 infection after mRNA 1273 vaccine: review of the most frequently asked questions. <i>Infezioni in Medicina</i> , 2021, 29, 305-311.	1.1	2
762	Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks. <i>Microbiology Spectrum</i> , 2021, 9, e0022421.	3.0	8
763	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. <i>Wellcome Open Research</i> , 0, 6, 220.	1.8	6
766	Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. <i>PLoS ONE</i> , 2021, 16, e0252849.	2.5	11
768	Highly active engineered IgG3 antibodies against SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	48
769	Evaluation of spike protein antigens for SARS-CoV-2 serology. <i>Journal of Virological Methods</i> , 2021, 296, 114222.	2.1	10

#	ARTICLE	IF	CITATIONS
770	Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115430.	1.8	0
771	Humoral immune mechanisms involved in protective and pathological immunity during COVID-19. <i>Human Immunology</i> , 2021, 82, 733-745.	2.4	47
772	A rapid quantitative on-site coronavirus disease 19 serological test. <i>Biosensors and Bioelectronics</i> , 2021, 191, 113406.	10.1	10
773	Current status, advances, challenges and perspectives on biosensors for COVID-19 diagnosis in resource-limited settings. <i>Sensors and Actuators Reports</i> , 2021, 3, 100025.	4.4	24
774	An electrochemical immunosensor using SARS-CoV-2 spike protein-nickel hydroxide nanoparticles bio-conjugate modified SPCE for ultrasensitive detection of SARS-CoV-2 antibodies. <i>Microchemical Journal</i> , 2021, 170, 106718.	4.5	47
775	One-pot pre-coated interface proximity extension assay for ultrasensitive co-detection of anti-SARS-CoV-2 antibodies and viral RNA. <i>Biosensors and Bioelectronics</i> , 2021, 193, 113535.	10.1	13
776	Ultra-sensitive and fast optical detection of the spike protein of the SARS-CoV-2 using AgNPs/SiNWs nanohybrid based sensors. <i>Surfaces and Interfaces</i> , 2021, 27, 101454.	3.0	27
777	SERS-based lateral flow immunoassay for sensitive and simultaneous detection of anti-SARS-CoV-2 IgM and IgG antibodies by using gap-enhanced Raman nanotags. <i>Sensors and Actuators B: Chemical</i> , 2021, 348, 130706.	7.8	57
778	CRISPR-Cas based virus detection: Recent advances and perspectives. <i>Biosensors and Bioelectronics</i> , 2021, 193, 113541.	10.1	110
779	Magnetofluidic immuno-PCR for point-of-care COVID-19 serological testing. <i>Biosensors and Bioelectronics</i> , 2022, 195, 113656.	10.1	18
781	Demographic Characteristics of Adults with IgG Antibodies to Prior Symptomatic SARS-CoV-2 Infection. <i>Journal of General Internal Medicine</i> , 2021, 36, 1156-1158.	2.6	0
782	Preventing Coronavirus Disease 2019 in Kidney Transplant Recipients: Where Should We Begin?. <i>Nephron</i> , 2021, 145, 280-284.	1.8	2
784	Modifying laboratory testing via home brew during the COVID-19 pandemic. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e93.	0.6	3
785	Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. <i>Epidemiology and Infection</i> , 2021, 149, e140.	2.1	9
788	Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma. <i>Journal of Infectious Diseases</i> , 2021, 223, 743-751.	4.0	17
789	The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 Pandemic. <i>Academic Pathology</i> , 2021, 8, 23742895211006818.	1.1	5
794	Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. <i>PLoS ONE</i> , 2021, 16, e0245382.	2.5	14
795	Development and Characterization of a Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike Antibodies. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
797	Current advances in the detection of COVID-19 and evaluation of the humoral response. Analyst, The, 2021, 146, 382-402.	3.5	25
798	Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Frontiers in Immunology, 2020, 11, 628971.	4.8	51
799	Microscopy-based assay for semi-quantitative detection of SARS-CoV-2 specific antibodies in human sera. BioEssays, 2021, 43, e2000257.	2.5	22
800	The outlook for diagnostic purposes of the 2019 novel coronavirus disease. Journal of Cellular Physiology, 2020, 235, 9211-9229.	4.1	35
801	6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort. Wiener Klinische Wochenschrift, 2021, 133, 351-358.	1.9	10
802	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. ACS Omega, 2021, 6, 85-102.	3.5	54
803	SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature, 2020, 587, 270-274.	27.8	1,115
804	Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2021, 223, 957-970.	4.0	64
805	Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting. Journal of Infectious Diseases, 2021, 223, 971-980.	4.0	20
806	Universal Polymerase Chain Reaction and Antibody Testing Demonstrate Little to No Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in a Rural Community. Open Forum Infectious Diseases, 2021, 8, ofaa531.	0.9	9
807	Breast Reconstruction in a Coronavirus Disease 2019 Hub. Plastic and Reconstructive Surgery - Global Open, 2020, 8, e3043.	0.6	12
808	Diagnostic testing for SARS-CoV-2/COVID19. Current Opinion in Pediatrics, 2021, 33, 122-128.	2.0	18
809	Identification of Immunohistochemical Reagents for In Situ Protein Expression Analysis of Coronavirus-associated Changes in Human Tissues. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 5-12.	1.2	26
936	Accuracy of serological testing for SARS-CoV-2 antibodies: First results of a large mixed-method evaluation study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 853-865.	5.7	34
937	A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS Journal, 2020, 287, 3633-3650.	4.7	192
938	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Science Immunology, 2020, 5, .	11.9	172
939	Genome sequencing and the diagnosis of novel coronavirus (SARS-COV-2) in Africa: how far are we?. Pan African Medical Journal, 2020, 36, 80.	0.8	9
940	A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight, 2020, 5, .	5.0	193

#	ARTICLE	IF	CITATIONS
941	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight, 2020, 5, .	5.0	130
942	Convalescent plasma anti-“SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. Journal of Clinical Investigation, 2020, 130, 6728-6738.	8.2	172
943	COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. Journal of Clinical Investigation, 2020, 130, 6366-6378.	8.2	97
944	Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population. F1000Research, 2020, 9, 285.	1.6	19
945	Expected immune recognition of COVID-19 virus by memory from earlier infections with common coronaviruses in a large part of the world population. F1000Research, 2020, 9, 285.	1.6	20
946	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. Wellcome Open Research, 2020, 5, 139.	1.8	179
947	Capillary whole-blood IgG-IgM COVID-19 self-test as a serological screening tool for SARS-CoV-2 infection adapted to the general public. PLoS ONE, 2020, 15, e0240779.	2.5	9
948	Testing IgG antibodies against the RBD of SARS-CoV-2 is sufficient and necessary for COVID-19 diagnosis. PLoS ONE, 2020, 15, e0241164.	2.5	47
949	Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study. PLoS ONE, 2020, 15, e0242917.	2.5	12
950	Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome. PLoS ONE, 2020, 15, e0243029.	2.5	22
951	mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2. PLoS Pathogens, 2020, 16, e1009163.	4.7	24
952	SARS-CoV-2 serosurvey in health care workers of the Veneto Region. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2107-2111.	2.3	64
953	IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2. Clinical Chemistry and Laboratory Medicine, 2020, 58, 2001-2008.	2.3	59
959	Mouse Model of SARS-CoV-2 Reveals Inflammatory Role of Type I Interferon Signaling. SSRN Electronic Journal, 2020, , 3628297.	0.4	3
960	The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of Germinal Centers in COVID-19. SSRN Electronic Journal, 2020, , 3652322.	0.4	20
961	An Affordable Anti-SARS-COV-2 Spike Protein Elisa Test for Early Detection of IgG Seroconversion Suited for Large-Scale Surveillance Studies in Low-Income Countries. SSRN Electronic Journal, 0, , .	0.4	5
962	Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future. Indian Journal of Ophthalmology, 2020, 68, 693.	1.1	78
963	Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. ELife, 2020, 9, .	6.0	26

#	ARTICLE	IF	CITATIONS
964	Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand. <i>PeerJ</i> , 2020, 8, e9863.	2.0	12
965	The Possibility and Cause of Relapse After Previously Recovering From COVID-19: A Systematic Review. <i>Cureus</i> , 2020, 12, e10264.	0.5	10
966	Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage. <i>Journal of Infectious Diseases</i> , 2021, 224, 1861-1872.	4.0	6
967	Comprehensive serological strategy for the diagnosis and monitoring of SARS-CoV-2. From infection to vaccine control. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 44-45.	1.3	0
968	Praxis of Technology and Tools in COVID-19 Response. <i>Research Journal of Pharmacy and Technology</i> , 2021, , 4808-4814.	0.8	1
969	Persistence of infectious SARS-CoV-2 particles for up to 37 days in patients with mild COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2053-2066.	5.7	8
970	Serum IgG anti-SARS-CoV-2 Binding Antibody Level Is Strongly Associated With IgA and Functional Antibody Levels in Adults Infected With SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 693462.	4.8	6
971	Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. <i>Science Immunology</i> , 2021, 6, eabm3131.	11.9	37
972	Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination. <i>Journal of Immunological Methods</i> , 2021, 499, 113165.	1.4	6
973	Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen. <i>Translational Research</i> , 2022, 240, 26-32.	5.0	12
974	Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children. <i>Frontiers in Immunology</i> , 2021, 12, 753435.	4.8	13
975	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> , 2021, 600, 523-529.	27.8	194
976	Expression and characterization of SARS-CoV-2 spike proteins. <i>Nature Protocols</i> , 2021, 16, 5339-5356.	12.0	31
978	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	27.8	239
979	<scp>COVID</scp>-19 Vaccine Response in People with Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 89-100.	5.3	119
980	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868.	12.8	52
986	An Insight Into Detection Pathways/Biosensors of Highly Infectious Coronaviruses. <i>Molecular Biotechnology</i> , 2021, , 1.	2.4	3
987	No SARS-CoV-2 reinfection among staff health-care workers: Prospective hospital-wide screening during the first and second waves in Paris. <i>Journal of Clinical Virology</i> , 2021, 145, 104999.	3.1	2

#	ARTICLE	IF	CITATION
989	Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programmeâ€”The South African Experience. <i>Viruses</i> , 2021, 13, 2050.	3.3	5
990	Receptor binding domainâ€”IgG levels correlate with protection in residents facing SARSâ€”CoVâ€”2 B.1.1.7 outbreaks. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1885-1894.	5.7	13
992	Hydrogelâ€”Based Slow Release of a Receptorâ€”Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARSâ€”CoVâ€”2. <i>Advanced Materials</i> , 2021, 33, e2104362.	21.0	48
993	Immunogenicity and efficacy of â€”heterologous ChAdOx1â€”BNT162b2 vaccination. <i>Nature</i> , 2021, 600, 701-706.	27.8	180
994	Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. <i>Journal of General Virology</i> , 2021, 102, .	2.9	21
995	SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma. <i>Microbiology Spectrum</i> , 2021, 9, e0129821.	3.0	15
996	Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels. <i>Nature Communications</i> , 2021, 12, 6196.	12.8	15
997	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <i>Cell Discovery</i> , 2021, 7, 96.	6.7	21
998	Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies. <i>Vaccine</i> , 2021, 39, 7058-7065.	3.8	3
999	Dysregulated Immune Responses in COVID-19 Patients Correlating With Disease Severity and Invasive Oxygen Requirements. <i>Frontiers in Immunology</i> , 2021, 12, 769059.	4.8	16
1000	Recent findings and applications of biomedical engineering for COVID-19 diagnosis: a critical review. <i>Bioengineered</i> , 2021, 12, 8594-8613.	3.2	10
1001	Solutions against emerging infectious and noninfectious human diseases through the application of baculovirus technologies. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 8195-8226.	3.6	18
1002	Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naÃ—ve CD8 T cells of unexposed individuals. <i>EBioMedicine</i> , 2021, 72, 103610.	6.1	24
1003	Analysis of IgG, IgA and IgM antibodies against SARSâ€”CoVâ€”2 spike protein S1 in convalescent and vaccinated patients with the Pfizerâ€”BioNTech and CanSinoBio vaccines. <i>Transboundary and Emerging Diseases</i> , 2022, 69, .	3.0	9
1004	High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort. <i>The Lancet Global Health</i> , 2021, 9, e1508-e1516.	6.3	10
1006	La respuesta inmune frente a SARS-CoV-2, ¿un arma de doble filo?. <i>Revista De InvestigaciÃ—n Y EducaciÃ—n En Ciencias De La Salud (RIECS)</i> , 2020, 5, 134-142.	0.0	0
1019	An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization. <i>Microbiology Spectrum</i> , 2021, 9, e0105921.	3.0	14
1020	Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital. <i>BMJ Open</i> , 2021, 11, e051045.	1.9	6

#	ARTICLE	IF	CITATIONS
1021	Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic. <i>Journal of Molecular Biology</i> , 2022, 434, 167332.	4.2	22
1022	BNT162b2 mRNA vaccine elicited antibody response in blood and milk of breastfeeding women. <i>Nature Communications</i> , 2021, 12, 6222.	12.8	44
1023	Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. <i>Immunity</i> , 2021, 54, 2908-2921.e6.	14.3	35
1024	Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago. <i>Annals of Epidemiology</i> , 2022, 66, 44-51.	1.9	10
1025	SPEEDS: A portable serological testing platform for rapid electrochemical detection of SARS-CoV-2 antibodies. <i>Biosensors and Bioelectronics</i> , 2022, 197, 113762.	10.1	33
1026	Immunochromatographic test for differentiation detection of IgM and IgG to SARS-CoV-2. <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2020, 65, 688-692.	0.5	1
1030	A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. <i>New Biotechnology</i> , 2022, 66, 46-52.	4.4	5
1031	Electrochemical sensors for the detection of SARS-CoV-2 virus. <i>Chemical Engineering Journal</i> , 2022, 430, 132966.	12.7	115
1033	The MultiBac BEVS: Basics, applications, performance and recent developments. <i>Methods in Enzymology</i> , 2021, 660, 129-154.	1.0	5
1034	Antibody Response to COVID-19 Virus “Heilongjiang Province and Gansu Province, China, 2020. <i>China CDC Weekly</i> , 2020, 2, 645-650.	2.3	0
1035	High Precursor Frequency and Promiscuity in $\gamma\delta$ T Cell Receptor Pairing Underpin CD8+ T-Cell Responses to an Immunodominant SARS-CoV-2 Nucleocapsid Epitope. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1036	The Frequency of SARS-CoV-2 Specific Memory B Cells in COVID-19 Recovered Patients Remain Stable While Antibodies Decay Over Time. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1037	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. <i>Immunity</i> , 2021, 54, 2877-2892.e7.	14.3	260
1038	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	3.3	20
1039	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	17.1	42
1041	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 31-56.	1.4	8
1042	Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19. <i>Journal of Immunological Methods</i> , 2022, 500, 113182.	1.4	8
1043	SARS-CoV-2 Serology Testing “A Laboratory Primer. <i>Clinics in Laboratory Medicine</i> , 2021, 42, 1-13.	1.4	0

#	ARTICLE	IF	CITATIONS
1044	Construction of Optimal SERS Hotspots Based on Capturing the Spike Receptor-Binding Domain (RBD) of SARS-CoV-2 for Highly Sensitive and Specific Detection by a Fish Model. <i>Analytical Chemistry</i> , 2021, 93, 16086-16095.	6.5	22
1057	Post COVID-19 Effects on Different Body Systems: A Literature Review. <i>Archives of Health Science</i> , 0, , 1-11.	0.0	0
1060	Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical Use. <i>Missouri Medicine</i> , 2020, 117, 184-195.	0.3	17
1061	A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19. <i>Iranian Journal of Medical Sciences</i> , 2021, 46, 151-168.	0.4	2
1062	Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab $\epsilon$ ) <sub>2</sub> fragment derived from equine polyclonal antibodies. <i>Toxicology and Applied Pharmacology</i> , 2022, 434, 115796.	2.8	3
1063	Long-term analysis of antibodies elicited by SPUTNIK V: A prospective cohort study in Tucum��n, Argentina. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100123.	2.6	21
1064	Overcoming the limitations of COVID-19 diagnostics with nanostructures, nucleic acid engineering, and additive manufacturing. <i>Current Opinion in Solid State and Materials Science</i> , 2022, 26, 100966.	11.5	9
1065	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. <i>Npj Vaccines</i> , 2021, 6, 143.	6.0	47
1066	Application of SARS-CoV-2 Serology to Address Public Health Priorities. <i>Frontiers in Public Health</i> , 2021, 9, 744535.	2.7	4
1070	Usefulness of ELISA Using Total Antibody against Plant-Expressed Recombinant Nucleocapsid Protein of SARS-CoV-2. <i>Microbiology Spectrum</i> , 2021, , e0067221.	3.0	4
1071	Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. <i>Cell Reports</i> , 2021, 37, 110114.	6.4	44
1073	Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases. <i>Frontiers in Immunology</i> , 2021, 12, 748291.	4.8	29
1074	Viable Severe Acute Respiratory Syndrome Coronavirus 2 Isolates Exhibit Higher Correlation With Rapid Antigen Assays Than Subgenomic RNA or Genomic RNA. <i>Frontiers in Microbiology</i> , 2021, 12, 718497.	3.5	6
1075	Whole blood��based measurement of SARS��CoV��2��specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid��organ cancers. <i>Immunology</i> , 2022, 165, 250-259.	4.4	21
1076	Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity. <i>Nature Communications</i> , 2021, 12, 6703.	12.8	36
1077	mRNA intramuscular vaccination produces a robust IgG antibody response in advanced neuromuscular disease. <i>Neuromuscular Disorders</i> , 2022, 32, 33-35.	0.6	6
1078	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	3.3	11
1080	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	5.6	72

#	ARTICLE	IF	CITATIONS
1081	Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae <i>Chlamydomonas reinhardtii</i> . PLoS ONE, 2021, 16, e0257089.	2.5	20
1082	The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. Clinical Science, 2021, 135, 2667-2689.	4.3	97
1084	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- $\alpha$ inhibitors. Med, 2021, 2, 1327-1341.e4.	4.4	31
1085	Sustained Delivery of SARS-CoV-2 RBD Subunit Vaccine Using a High Affinity Injectable Hydrogel Scaffold. Advanced Healthcare Materials, 2022, 11, e2101714.	7.6	17
1086	Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study. Viruses, 2021, 13, 2270.	3.3	5
1087	Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections. Frontiers in Public Health, 2021, 9, 766871.	2.7	10
1088	Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. Nature Communications, 2021, 12, 6844.	12.8	22
1089	Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Frontiers in Immunology, 2021, 12, 791764.	4.8	14
1090	Point-of-Care Testingâ€”The Key in the Battle against SARS-CoV-2 Pandemic. Micromachines, 2021, 12, 1464.	2.9	18
1091	SARS-CoV-2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort. Paediatric and Perinatal Epidemiology, 2022, 36, 466-475.	1.7	17
1092	SARS-CoV-2 Antibody Response among Women Infected during Pregnancy. American Journal of Perinatology, 2022, 39, 707-713.	1.4	4
1093	Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. Frontiers in Public Health, 2021, 9, 724398.	2.7	8
1094	Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins. PLoS ONE, 2021, 16, e0258645.	2.5	13
1095	Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants. Microbiology Spectrum, 2021, 9, e0056021.	3.0	20
1096	The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous Expression. Biomolecules, 2021, 11, 1812.	4.0	22
1097	Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. Heliyon, 2021, 7, e08444.	3.2	8
1098	Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes. Vaccines, 2021, 9, 1419.	4.4	4
1099	Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab. Internal Medicine, 2021, 60, 3827-3831.	0.7	8

#	ARTICLE	IF	CITATIONS
1100	Rapid test to assess the escape of SARS-CoV-2 variants of concern. Science Advances, 2021, 7, eabl7682.	10.3	21
1101	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. RSC Drug Discovery Series, 2021, , 45-60.	0.3	0
1102	SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients. Clinics, 2021, 76, e3548.	1.5	3
1103	Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. World Journal of Clinical Cases, 2022, 10, 1-11.	0.8	241
1104	All-solid-state SARS-CoV-2 protein biosensor employing colloidal quantum dots-modified electrode. Biosensors and Bioelectronics, 2022, 202, 113974.	10.1	29
1105	ACE2-IgG1 fusions with improved inÂvitro and inÂvivo activity against SARS-CoV-2. IScience, 2022, 25, 103670.	4.1	29
1106	Magnet-assisted electrochemical immunosensor based on surface-clean Pd-Au nanosheets for sensitive detection of SARS-CoV-2 spike protein. Electrochimica Acta, 2022, 404, 139766.	5.2	26
1107	ĐžĐĳĐžĐ'Đ•Đ~Đ'ĐžĐĳĐŒĐ† Đ†ĐœĐŒĐĐ†ĐŒĐ•ĐŒĐŒ ĐŸĐĐ~ COVID-19. Immunology and Allergy Science and Practice, 2020, , 15-15.		
1108	Inducible protein expression in piggyBac transposase mediated stable HEK293 cell pools. Methods in Enzymology, 2021, 660, 321-339.	1.0	1
1109	Severe acute respiratory syndrome coronavirus-2 IgG antibodies among health-care workers in a tertiary care hospital in Delhi India. Journal of Patient Safety & Infection Control, 2021, 9, 48.	0.1	0
1110	CORONAVIRUS DISEASE (COVID-19). CHALLENGES AND PROSPECTS OF SPECIFIC DIAGNOSTICS. Mikrobiologia I Biotechnologia, 2021, , 6-44.	0.1	0
1111	STRUCTURAL PROTEINS OF THE SARS-COV-2 CORONAVIRUS: ROLE, IMMUNOGENICITY, SUPERANTIGENIC PROPERTIES AND POTENTIAL USE FOR THERAPEUTIC PURPOSES. , 2021, 78, 18-27.		2
1112	A collaborative robotic solution to partly automate SARS-CoV-2 serological tests in small facilities. SLAS Technology, 2022, 27, 100-106.	1.9	4
1113	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature, 2022, 602, 682-688.	27.8	395
1114	A High-throughput Automated ELISA Assay for Detection of IgG Antibodies to the SARS-CoV-2 Spike Protein. Bio-protocol, 2022, 12, e4301.	0.4	0
1115	Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals. Pathogens, 2022, 11, 186.	2.8	4
1117	Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Medicine, 2022, 20, 26.	5.5	152
1120	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. RSC Medicinal Chemistry, 2022, 13, 647-675.	3.9	3

#	ARTICLE	IF	CITATIONS
1121	Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera. <i>Antibodies</i> , 2022, 11, 3.	2.5	1
1122	Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. <i>Vaccines</i> , 2022, 10, 153.	4.4	20
1123	Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. <i>Cell Host and Microbe</i> , 2022, 30, 83-96.e4.	11.0	64
1124	A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. <i>Science Advances</i> , 2022, 8, eabh3827.	10.3	27
1125	Detection of anti-SARS-CoV-2 antibody for the diagnosis of past-COVID-19 infection cases using a liquid-crystal-based immunosensor. <i>Liquid Crystals</i> , 2022, 49, 1285-1296.	2.2	4
1126	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients. <i>Blood Cancer Journal</i> , 2022, 12, 8.	6.2	5
1127	Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations. <i>Journal of Clinical Virology</i> , 2022, 146, 105061.	3.1	14
1128	Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. <i>EBioMedicine</i> , 2022, 75, 103805.	6.1	60
1131	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	6.5	6
1132	Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. <i>Nature Communications</i> , 2022, 13, 140.	12.8	22
1133	Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. <i>Frontiers in Immunology</i> , 2022, 13, 830710.	4.8	19
1134	Immunoglobulin-G antibodies against severe acute respiratory syndrome “ coronavirus-2 among health-care workers: A serosurveillance study from India. <i>International Journal of Applied &amp; Basic Medical Research</i> , 2022, 12, 18.	0.5	1
1135	SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. <i>PLoS ONE</i> , 2022, 17, e0262169.	2.5	29
1136	Structural insights in cell-type specific evolution of intra-host diversity by SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 222.	12.8	23
1137	Construction of SARS-CoV-2 virus-like particles in plant. <i>Scientific Reports</i> , 2022, 12, 1005.	3.3	26
1138	SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study. <i>Vaccine</i> , 2022, 40, 206-212.	3.8	20
1139	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1.	7.0	144
1140	IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools. <i>PLoS ONE</i> , 2022, 17, e0262162.	2.5	23

#	ARTICLE	IF	CITATIONS
1141	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 405.	12.8	92
1143	Vaccination Induces Stronger Spike Immunity and Better Protection Against SARS-CoV-2 Infection in COVID-19 Recovered Subjects than in Naïve Individuals. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1144	Innovative FO-SPR Label-free Strategy for Detecting Anti-RBD Antibodies in COVID-19 Patient Serum and Whole Blood. <i>ACS Sensors</i> , 2022, 7, 477-487.	7.8	31
1145	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. <i>Cell</i> , 2022, 185, 1008-1024.e15.	28.9	101
1146	A quantitative assay for detection of SARS-CoV-2 neutralizing antibodies. <i>Journal of Clinical Virology</i> , 2022, 147, 105064.	3.1	6
1147	Designed SARS-CoV-2 receptor binding domain variants form stable monomers. <i>Biotechnology Journal</i> , 2022, 17, e2100422.	3.5	8
1148	Immunity to SARS-CoV-2 up to 15 months after infection. <i>IScience</i> , 2022, 25, 103743.	4.1	56
1150	SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 556-563.	4.3	6
1151	Zinc associated nanomaterials and their intervention in emerging respiratory viruses: Journey to the field of biomedicine and biomaterials. <i>Coordination Chemistry Reviews</i> , 2022, 457, 214402.	18.8	28
1152	Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 248-256.	1.3	13
1154	Sustained Antibody-Dependent NK Cell Functions in Mild COVID-19 Outpatients During Convalescence. <i>Frontiers in Immunology</i> , 2022, 13, 796481.	4.8	7
1155	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	28.9	189
1156	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals. <i>Viruses</i> , 2022, 14, 370.	3.3	5
1158	Thermally Responsive Alkane Partitions for Assay Automation. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 8865-8875.	8.0	1
1159	Expression, purification and characterization of SARS-CoV-2 spike RBD in ExpiCHO cells. <i>Protein Expression and Purification</i> , 2022, 194, 106071.	1.3	11
1160	<i>Streptococcus pneumoniae</i> colonization associates with impaired adaptive immune responses against SARS-CoV-2. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	33
1161	The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin $\alpha 5 \beta 1$ and NF- $\kappa$ B signaling. <i>Journal of Biological Chemistry</i> , 2022, 298, 101695.	3.4	74
1162	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. <i>Clinical Biochemistry</i> , 2022, 101, 19-25.	1.9	5

#	ARTICLE	IF	CITATIONS
1163	Isothermal gene amplification coupled MALDI-TOF MS for SARS-CoV-2 detection. <i>Talanta</i> , 2022, 242, 123297.	5.5	12
1164	Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire. <i>Journal of Proteome Research</i> , 2022, 21, 274-288.	3.7	16
1165	Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. <i>Nature</i> , 0, , .	27.8	56
1169	Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0265621.	4.1	14
1170	Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor. <i>ELife</i> , 2021, 10, .	6.0	29
1171	Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases. <i>Kobe Journal of Medical Sciences</i> , 2021, 67, E55-E60.	0.2	0
1172	A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. <i>Clinical and Translational Immunology</i> , 2022, 11, e1380.	3.8	65
1175	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	3.3	34
1176	Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients. <i>PLoS ONE</i> , 2022, 17, e0261979.	2.5	10
1177	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). <i>Scientific Reports</i> , 2022, 12, 2552.	3.3	23
1179	Low-entry-barrier point-of-care testing of anti-SARS-CoV-2 IgG in the population of Upper Austria from December 2020 until April 2021—a feasible surveillance strategy for post-pandemic monitoring?. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 3291-3299.	3.7	0
1180	Anti-RBD IgA and IgG Response and Transmission in Breast Milk of Anti-SARS-CoV-2 Vaccinated Mothers. <i>Pathogens</i> , 2022, 11, 286.	2.8	14
1181	COVID-19 mRNA vaccines: Platforms and current developments. <i>Molecular Therapy</i> , 2022, 30, 1850-1868.	8.2	102
1182	Comparative Investigation of Methods for Analysis of SARS-CoV-2-Spike-Specific Antisera. <i>Viruses</i> , 2022, 14, 410.	3.3	3
1184	Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses. <i>Journal of Clinical Medicine</i> , 2022, 11, 1503.	2.4	4
1185	Comparison of Seroconversion in Children and Adults With Mild COVID-19. <i>JAMA Network Open</i> , 2022, 5, e221313.	5.9	55
1186	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. <i>Wellcome Open Research</i> , 0, 6, 220.	1.8	1
1187	A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 103960.	4.1	16

#	ARTICLE	IF	CITATIONS
1188	Possible Cross-Reactivity of Feline and White-Tailed Deer Antibodies against the SARS-CoV-2 Receptor Binding Domain. <i>Journal of Virology</i> , 2022, 96, e0025022.	3.4	10
1189	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	27.8	117
1191	Sensitive and specific serological ELISA for the detection of SARS-CoV-2 infections. <i>Virology Journal</i> , 2022, 19, 50.	3.4	15
1192	Nanoplasmonic multiplex biosensing for COVID-19 vaccines. <i>Biosensors and Bioelectronics</i> , 2022, 208, 114193.	10.1	10
1193	Microfluidic Antibody Affinity Profiling Reveals the Role of Memory Reactivation and Cross-Reactivity in the Defense Against SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2022, 8, 790-799.	3.8	8
1194	A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs. <i>Viruses</i> , 2022, 14, 562.	3.3	2
1197	Prevalence of anti-severe acute respiratory syndrome coronavirus 2 antibodies in cats in Germany and other European countries in the early phase of the coronavirus disease-19 pandemic. <i>Zoonoses and Public Health</i> , 2022, 69, 439-450.	2.2	12
1199	A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	3.3	5
1200	Hydrophobic Localized Enrichment of Co-reactants to Enhance Electrochemiluminescence of Conjugated Polymers for Detecting SARS-CoV-2 Nucleocapsid Proteins. <i>Analytical Chemistry</i> , 2022, 94, 4446-4454.	6.5	15
1202	Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103737.	2.0	13
1203	Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2977.	4.1	4
1204	Induction of broadly reactive influenza antibodies increases susceptibility to autoimmunity. <i>Cell Reports</i> , 2022, 38, 110482.	6.4	7
1205	De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. <i>Nature Communications</i> , 2022, 13, 1547.	12.8	159
1206	A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies. <i>Vaccine</i> , 2022, 40, 1958-1967.	3.8	5
1208	Antibody Response to SARS-CoV-2 in Relation to the Contributing Factors in COVID-19 Patients. <i>Viral Immunology</i> , 2022, 35, 142-149.	1.3	3
1209	An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas Transplants. <i>Transplantation</i> , 2022, 106, 1421-1429.	1.0	7
1210	Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. <i>JAMA Oncology</i> , 2022, 8, 748.	7.1	20
1211	Advances in purification of SARS-CoV-2 spike ectodomain protein using high-throughput screening and non-affinity methods. <i>Scientific Reports</i> , 2022, 12, 4458.	3.3	4

#	ARTICLE	IF	CITATIONS
1212	Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors. <i>Biomedical Optics Express</i> , 2022, 13, 2130.	2.9	10
1213	Low Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community-Based Serological Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac055.	0.9	4
1217	A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines. <i>Vaccine</i> , 2022, 40, 2551-2560.	3.8	11
1218	Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds. <i>GeroScience</i> , 2022, 44, 1229-1240.	4.6	10
1219	A rapid antibody screening haemagglutination test for predicting immunity to SARS-CoV-2 variants of concern. <i>Communications Medicine</i> , 2022, 2, .	4.2	3
1223	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	14.3	86
1225	Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals. <i>EBioMedicine</i> , 2022, 78, 103972.	6.1	31
1226	BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?. <i>EMBO Molecular Medicine</i> , 2022, 14, e15326.	6.9	30
1227	SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. <i>Nature Immunology</i> , 2022, 23, 781-790.	14.5	116
1228	A Cell-Free Assay for Rapid Screening of Inhibitors of hACE2-Receptor-SARS-CoV-2-Spike Binding. <i>ACS Synthetic Biology</i> , 2022, 11, 1389-1396.	3.8	0
1229	Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak. <i>PLoS ONE</i> , 2022, 17, e0266270.	2.5	11
1230	Intranasal delivery of SARS-CoV-2 spike protein is sufficient to cause olfactory damage, inflammation and olfactory dysfunction in zebrafish. <i>Brain, Behavior, and Immunity</i> , 2022, 102, 341-359.	4.1	27
1231	The immunologic response to severe acute respiratory syndrome coronavirus 2. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 495-505.	2.2	5
1232	Functional Trimeric SARS-CoV-2 Envelope Protein Expressed in Stable CHO Cells. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 779359.	4.1	4
1233	Coronavirus Disease 2019 (COVID-19): Emerging detection technologies and auxiliary analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24152.	2.1	10
1234	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	3.5	0
1235	Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 549-555.	1.2	8
1237	Plasmonic Metasurfaces for Medical Diagnosis Applications: A Review. <i>Sensors</i> , 2022, 22, 133.	3.8	23

#	ARTICLE	IF	CITATIONS
1240	No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study. <i>Scientific Reports</i> , 2021, 11, 24198.	3.3	0
1241	Current aspects of COVID-19 vaccine prophylaxis: big steps from laboratory to clinical practice. <i>Problemy Zdorov'ia i Ākologii</i> , 2021, 18, 5-16.	0.1	0
1242	Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 759688.	4.8	29
1244	Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 75, e705-e714.	5.8	10
1245	Highly Sensitive and Specific SARS-CoV-2 Serological Assay Using a Magnetic Modulation Biosensing System. <i>Biosensors</i> , 2022, 12, 7.	4.7	3
1246	Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. <i>Cell Reports</i> , 2021, 37, 110169.	6.4	34
1248	Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. <i>PLoS Biology</i> , 2021, 19, e3001384.	5.6	15
1249	Dried blood spot specimens for SARS-CoV-2 antibody testing: A multi-site, multi-assay comparison. <i>PLoS ONE</i> , 2021, 16, e0261003.	2.5	24
1250	High-Yield Production of Receptor Binding Domain of SARS-CoV-2 Linked to Bacterial Flagellin in Plants Using Self-Replicating Viral Vector pEff. <i>Plants</i> , 2021, 10, 2682.	3.5	10
1251	Modeling serological testing to inform relaxation of social distancing for COVID-19 control. <i>Nature Communications</i> , 2021, 12, 7063.	12.8	11
1252	An Integrated Platform for Serological Detection and Vaccination of COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 771011.	4.8	6
1255	Insect Cells for High-Yield Production of SARS-CoV-2 Spike Protein: Building a Virosome-Based COVID-19 Vaccine Candidate. <i>Pharmaceutics</i> , 2022, 14, 854.	4.5	8
1256	Deciphering the quality of SARS-CoV-2 specific T-cell response associated with disease severity, immune memory and heterologous response. <i>Clinical and Translational Medicine</i> , 2022, 12, e802.	4.0	8
1257	mRNA-1273 and Ad26.COVS.S vaccines protect against the B.1.621 variant of SARS-CoV-2. <i>Med</i> , 2022, 3, 309-324.e6.	4.4	6
1258	Potential importance of early treatment of SARS-CoV-2 infection in intestinal transplant patient: A case report. <i>World Journal of Transplantation</i> , 2022, 12, 72-78.	1.6	0
1260	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. <i>ACS Infectious Diseases</i> , 2022, 8, 1253-1264.	3.8	20
1262	Embedding Proteins within Spatially Controlled Hierarchical Nanoarchitectures for Ultrasensitive Immunoassay. <i>Analytical Chemistry</i> , 2022, 94, 6271-6280.	6.5	6
1263	Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold. <i>ACS Chemical Biology</i> , 2022, 17, 1184-1196.	3.4	5

#	ARTICLE	IF	CITATIONS
1265	Transient Expression of Glycosylated SARS-CoV-2 Antigens in <i>Nicotiana benthamiana</i> . <i>Plants</i> , 2022, 11, 1093.	3.5	12
1266	Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA. <i>Human Antibodies</i> , 2022, 30, 105-115.	1.5	5
1274	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. <i>Nature</i> , 2022, 607, 128-134.	27.8	197
1275	Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain. <i>MBio</i> , 2022, 13, e0358021.	4.1	12
1276	Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection.. <i>Acta Biomedica</i> , 2022, 92, e2021464.	0.3	0
1277	Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 487.	4.4	4
1278	Brief Research Report: Virus-Specific Humoral Immunity at Admission Predicts the Development of Respiratory Failure in Unvaccinated SARS-CoV-2 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 878812.	4.8	3
1279	Features of humoral immunity after COVID-19. <i>Medical Immunology (Russia)</i> , 2022, 24, 337-350.	0.4	2
1280	Gold Nanoparticle-Mediated Lateral Flow Assays for Detection of Host Antibodies and COVID-19 Proteins. <i>Nanomaterials</i> , 2022, 12, 1456.	4.1	17
1281	Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 895209.	4.8	13
1282	Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac. <i>Vaccine</i> , 2022, 40, 3320-3329.	3.8	6
1284	COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants. <i>Scientific Reports</i> , 2022, 12, 7168.	3.3	15
1285	Detecting anti-SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion. <i>Science Advances</i> , 2022, 8, eabn7424.	10.3	14
1286	Rapid Generation of In-House Serological Assays Is Comparable to Commercial Kits Critical for Early Response to Pandemics: A Case With SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	3
1288	Equipment-free, gold nanoparticle based semiquantitative assay of SARS-CoV-2-S1RBD IgG from fingertip blood: A practical strategy for on-site measurement of COVID-19 antibodies. <i>Talanta</i> , 2022, 246, 123498.	5.5	3
1289	Measuring Neutralizing Antibodies to SARS-CoV-2 Using Lentiviral Spike-Pseudoviruses. <i>Methods in Molecular Biology</i> , 2022, 2452, 305-314.	0.9	2
1290	SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents. <i>Cell Reports Medicine</i> , 2022, 3, 100651.	6.5	24
1291	A self-pressure-driven blood plasma-separation device for point-of-care diagnostics. <i>Talanta</i> , 2022, 247, 123562.	5.5	4

#	ARTICLE	IF	CITATIONS
1292	SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity. <i>Nature Communications</i> , 2022, 13, 2774.	12.8	21
1293	PARIS and SPARTA: Finding the Achillesâ€™ Heel of SARS-CoV-2. <i>MSphere</i> , 2022, 7, e0017922.	2.9	25
1294	SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. <i>ELife</i> , 2022, 11, .	6.0	34
1297	German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance. <i>Communications Medicine</i> , 2022, 2, .	4.2	6
1299	Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan. <i>Vaccines</i> , 2022, 10, 830.	4.4	5
1300	Persistence of Anti SARS-CoV-2 Antibodies in Breast Milk from Infected and Vaccinated Women after In Vitro-Simulated Gastrointestinal Digestion. <i>Nutrients</i> , 2022, 14, 2117.	4.1	6
1301	SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. <i>Nature Communications</i> , 2022, 13, .	12.8	22
1302	Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. <i>Npj Vaccines</i> , 2022, 7, .	6.0	8
1303	COVID-19 Diagnostics: A Panoramic View on Its Present Scenario, Challenges and Solutions. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> , 0, , .	1.0	2
1304	Development of Ethical COVID-19 Antibody Testing that Adheres to Pro-Life Principles. <i>Linacre quarterly, The</i> , 0, , 002436392210959.	0.2	0
1305	Evaluation of a photoelectrochemical platform based on strontium titanate, sulfur doped carbon nitride and palladium nanoparticles for detection of SARS-CoV-2 spike glycoprotein S1. <i>Biosensors and Bioelectronics: X</i> , 2022, 11, 100167.	1.7	4
1306	Sensitive methods for detection of SARS-CoV-2 RNA. <i>Methods in Microbiology</i> , 2022, , 1-26.	0.8	2
1307	SARS-CoV-2 infection in patients with inborn errors of immunity due to DNA repair defects. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, , .	2.0	3
1308	No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination. <i>PLoS Biology</i> , 2022, 20, e3001506.	5.6	10
1309	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	5.0	24
1311	The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination. <i>Vaccines</i> , 2022, 10, 794.	4.4	5
1312	SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e052130.	1.9	2
1313	Principles of SARS-CoV-2 glycosylation. <i>Current Opinion in Structural Biology</i> , 2022, 75, 102402.	5.7	27

#	ARTICLE	IF	CITATIONS
1314	A Universal Fluorescent Immunochromatography Assay Based on Quantum Dot Nanoparticles for the Rapid Detection of Specific Antibodies against SARS-CoV-2 Nucleocapsid Protein. International Journal of Molecular Sciences, 2022, 23, 6225.	4.1	6
1315	Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months. PLoS Pathogens, 2022, 18, e1010569.	4.7	6
1316	Production of novel SARS-CoV-2 Spike truncations in Chinese hamster ovary cells leads to high expression and binding to antibodies. Biotechnology Journal, 0, , 2100678.	3.5	2
1317	SERS-based assay for multiplexed detection of cross-reactivity and persistence of antibodies against the spike of the native, P.1 and B.1.617.2 SARS-CoV-2 in non-hospitalised adults. Sensors & Diagnostics, 2022, 1, 851-866.	3.8	3
1318	An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19. Frontiers in Immunology, 0, 13, .	4.8	7
1319	Near-Infrared-Emissive AIE Bioconjugates: Recent Advances and Perspectives. Molecules, 2022, 27, 3914.	3.8	8
1321	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. Wellcome Open Research, 0, 6, 220.	1.8	4
1322	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
1323	SARS-CoV-2-specific T cell memory with common TCR $\alpha$ motifs is established in unvaccinated children who seroconvert after infection. Immunity, 2022, 55, 1299-1315.e4.	14.3	23
1324	Blood and saliva SARS-CoV-2 antibody levels in self-collected dried spot samples. Medical Microbiology and Immunology, 2022, 211, 173-183.	4.8	5
1325	Inhibitors of Activin Receptor-like Kinase 5 Interfere with SARS-CoV-2 S-Protein Processing and Spike-Mediated Cell Fusion via Attenuation of Furin Expression. Viruses, 2022, 14, 1308.	3.3	1
1327	The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization. MSphere, 2022, 7, .	2.9	16
1329	Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. BMC Medicine, 2022, 20, .	5.5	13
1330	An updated review of SARS-CoV-2 detection methods in the context of a novel coronavirus pandemic. Bioengineering and Translational Medicine, 2023, 8, .	7.1	19
1331	A diminished immune response underlies age-related SARS-CoV-2 pathologies. Cell Reports, 2022, 39, 111002.	6.4	20
1332	Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiology Spectrum, 2022, 10, .	3.0	14
1333	A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. Vaccines, 2022, 10, 914.	4.4	3
1334	SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up. Vaccine: X, 2022, 11, 100175.	2.1	5

#	ARTICLE	IF	CITATIONS
1335	Validation of laboratory developed serology assays for detection of IgG antibody to severe acute respiratory syndrome coronavirus 2 in the South African population. <i>Journal of Virological Methods</i> , 2022, 307, 114571.	2.1	2
1336	An impedimetric biosensor for COVID-19 serology test and modification of sensor performance via dielectrophoresis force. <i>Biosensors and Bioelectronics</i> , 2022, 213, 114476.	10.1	20
1337	Robust humoral immune response after boosting in children with Multisystem Inflammatory Syndrome in Children. <i>IDCases</i> , 2022, 29, e01569.	0.9	1
1338	Landscape Determinants of Infectivity and Insights into Vaccine Development and Effectiveness - Novel Coronavirus. <i>Letters in Drug Design and Discovery</i> , 2023, 20, 119-143.	0.7	1
1339	Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1050.	4.4	3
1340	Association of SARS-CoV-2 Seropositivity and Symptomatic Reinfection in Children in Nicaragua. <i>JAMA Network Open</i> , 2022, 5, e2218794.	5.9	8
1341	Antibody-Î“Invertase Fusion Protein Enables Quantitative Detection of SARS-CoV-2 Antibodies Using Widely Available Glucometers. <i>Journal of the American Chemical Society</i> , 2022, 144, 11226-11237.	13.7	13
1342	Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital. <i>Vaccines</i> , 2022, 10, 1031.	4.4	6
1343	Tissue immunity to SARS-â€CoV-â€2: Role in protection and immunopathology*. <i>Immunological Reviews</i> , 2022, 309, 25-39.	6.0	11
1344	An RBD-Based Diagnostic Method Useful for the Surveillance of Protective Immunity against SARS-CoV-2 in the Population. <i>Diagnostics</i> , 2022, 12, 1629.	2.6	5
1345	Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents. <i>Vaccines</i> , 2022, 10, 1098.	4.4	4
1346	Clinical and Serological Findings of COVID-19 Participants in the Region of Makkah, Saudi Arabia. <i>Diagnostics</i> , 2022, 12, 1725.	2.6	0
1347	Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines. <i>IScience</i> , 2022, 25, 104739.	4.1	4
1348	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COVS vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	10
1349	From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics. <i>Biochemical Engineering Journal</i> , 2022, 186, 108537.	3.6	22
1351	Guardians of the oral and nasopharyngeal galaxy: <sc>IgA</sc> and protection against <sc>SARS-â€CoV</sc>-â€2 infection*. <i>Immunological Reviews</i> , 2022, 309, 75-85.	6.0	32
1352	Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022, 20, 98.	3.3	5
1353	Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104766.	4.1	13

#	ARTICLE	IF	CITATIONS
1354	Directly immersible silicon photonic probes: Application to rapid SARS-CoV-2 serological testing. Biosensors and Bioelectronics, 2022, 215, 114570.	10.1	8
1355	GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2. Pathogens, 2022, 11, 806.	2.8	3
1356	Proof-of-concept for speedy development of rapid and simple at-home method for potential diagnosis of early COVID-19 mutant infections using nanogold and aptamer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 45, 102590.	3.3	3
1357	Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2. ACS Infectious Diseases, 2022, 8, 1468-1479.	3.8	4
1358	Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. Journal of Diabetes and Metabolic Disorders, 2022, 21, 1763-1783.	1.9	4
1359	Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. Frontiers in Immunology, 0, 13, .	4.8	3
1360	Kinetics of anti-SARS-CoV-2 responses post complete vaccination with coronavac: A prospective study in 50 health workers. Journal of Public Health Research, 2022, 11, 227990362211041.	1.2	1
1361	Understanding the Excitation Wavelength Dependence and Thermal Stability of the SARS-CoV-2 Receptor-Binding Domain Using Surface-Enhanced Raman Scattering and Machine Learning. ACS Photonics, 2022, 9, 2963-2972.	6.6	10
1363	SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients â€“ a comparative long term post-infection study. Frontiers in Immunology, 0, 13, .	4.8	4
1364	De novo emergence of SARSâ€“CoVâ€“2 spike mutations in immunosuppressed patients. Transplant Infectious Disease, 2022, 24, .	1.7	9
1367	A Rapid and Sensitive Microfluidics-Based Tool for Seroprevalence Immunity Assessment of COVID-19 and Vaccination-Induced Humoral Antibody Response at the Point of Care. Biosensors, 2022, 12, 621.	4.7	7
1368	Engineered multivalent self-assembled binder protein against SARS-CoV-2 RBD. Biochemical Engineering Journal, 2022, 187, 108596.	3.6	2
1369	Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19. Journal of Clinical Virology Plus, 2022, 2, 100101.	1.0	5
1370	Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. Vaccine, 2022, 40, 5892-5903.	3.8	6
1371	SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants. MBio, 2022, 13, .	4.1	6
1372	Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples. Scientific World Journal, The, 2022, 2022, 1-7.	2.1	2
1373	Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer. Cell Reports Methods, 2022, 2, 100273.	2.9	5
1374	Integration of Multiple Interferometers in Highly Multiplexed Diagnostic KITs to Evaluate Several Biomarkers of COVID-19 in Serum. Biosensors, 2022, 12, 671.	4.7	2

#	ARTICLE	IF	CITATIONS
1376	Recent Advances in CRISPR-Based Biosensors for Point-of-Care Pathogen Detection. CRISPR Journal, 2022, 5, 500-516.	2.9	14
1377	IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi. PLoS ONE, 2022, 17, e0271259.	2.5	6
1378	Serum N-glycomic profiling may provide potential signatures for surveillance of COVID-19. Glycobiology, 0, , .	2.5	1
1379	Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. Journal of Experimental Medicine, 2022, 219, .	8.5	12
1380	A lab-on-a-chip for the concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in saliva and plasma. Nature Biomedical Engineering, 2022, 6, 968-978.	22.5	109
1381	Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2Â and S proteins: mass screening. Applied Microbiology and Biotechnology, 0, , .	3.6	2
1382	The SARS-CoV-2 Antibodies, Their Diagnostic Utility, and Their Potential for Vaccine Development. Vaccines, 2022, 10, 1346.	4.4	4
1383	SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021. PLOS Global Public Health, 2022, 2, e0000883.	1.6	5
1384	Ultrarapid and ultrasensitive detection of SARSâ€CoVâ€2 antibodies in COVIDâ€19 patients via a 3Dâ€printed nanomaterialâ€based biosensing platform. Journal of Medical Virology, 2022, 94, 5808-5826.	5.0	8
1386	Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people. JCI Insight, 2022, 7, .	5.0	10
1387	DEVELOPMENT AND VALIDATION OF AN ENZYME-LINKED IMMUNOASSAY KIT FOR DIAGNOSIS AND SURVEILLANCE OF COVID-19. Journal of Clinical Virology Plus, 2022, , 100103.	1.0	0
1388	Follow-up study of anti-SARS-CoV-2 IgG antibody response in COVID-19 patients up to 6 months after infection. Future Microbiology, 2022, 17, 1043-1049.	2.0	0
1389	Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study. EBioMedicine, 2022, 83, 104208.	6.1	29
1391	Fluorescent nanodiamond-based spin-enhanced lateral flow immunoassay for detection of SARS-CoV-2 nucleocapsid protein and spike protein from different variants. Analytica Chimica Acta, 2022, 1230, 340389.	5.4	20
1392	Oral inhalation of cannabidiol delivered from a metered dose inhaler to alleviate cytokine production induced by SARS-CoV-2 and pollutants. Journal of Drug Delivery Science and Technology, 2022, 76, 103805.	3.0	2
1393	Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease. Virology, 2022, 575, 83-90.	2.4	1
1394	Dynamics of SARS-CoV-2 exposure in Malawian infants between February 2020 and May 2021. Journal of Clinical Virology Plus, 2022, 2, 100110.	1.0	1
1395	Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents. Vaccine: X, 2022, 12, 100211.	2.1	4

#	ARTICLE	IF	CITATIONS
1396	Reliable estimation of SARS-CoV-2 anti-spike protein IgG titers from single dilution optical density values in serologic surveys. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 104, 115807.	1.8	0
1397	A Pilot Study: Validation of Dried Blood Spots (DBS) to Assess SARS-CoV2 IgG Antibody Immunoassays in Hispanic Pregnant Women. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1398	Current clinical testing approach of COVID. , 2022, , 231-274.		0
1399	Nanotechnology-based bio-tools and techniques for COVID-19 management. , 2022, , 127-148.		0
1400	Biophysical and structural characterizations of the effects of mutations on the structureâ€“activity relationships of SARS-CoV-2 spike protein. <i>Methods in Enzymology</i> , 2022, , 299-321.	1.0	2
1401	Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9763.	4.1	17
1402	A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection inÂvivo. <i>Cell Reports Medicine</i> , 2022, 3, 100774.	6.5	14
1403	Utilization of Receptor-Binding Domain of SARS-CoV-2 Spike Protein ExpressedÂin Escherichia coli for the Development of Neutralizing Antibody Assay. <i>Molecular Biotechnology</i> , 0, , .	2.4	2
1404	Deep immunophenotyping reveals biomarkers of multisystemic inflammatory syndrome in children in a Latin American cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1074-1085.e11.	2.9	9
1405	Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	37
1406	COVID-19 Serosurvey of Frontline Healthcare Workers in Western Australia. <i>Journal of Epidemiology and Global Health</i> , 2022, 12, 472-477.	2.9	1
1407	Rational Design and Development of SARS-CoV-2 Serological Diagnostics by Immunoprecipitation-Targeted Proteomics. <i>Analytical Chemistry</i> , 2022, 94, 12990-12999.	6.5	8
1409	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
1410	Mamestra brassicae NIAS-Mb-32 cell strain 2g2 enables high-yield recombinant protein production in baculovirus-free and baculovirus-based insect cell expression. <i>Journal of Bioscience and Bioengineering</i> , 2022, 134, 432-440.	2.2	1
1411	Sensitive Serology Measurements in the Saliva of Individuals with COVID-19 Symptoms Using a Multiplexed Immunoassay. <i>journal of applied laboratory medicine</i> , The, 0, , .	1.3	0
1412	Durability of S-RBD IgG Antibody Levels after Sinovac Vaccination in Healthcare Workers. <i>Folia Medica Indonesiana</i> , 2022, 58, 234-241.	0.1	0
1413	Circulating multimeric immune complexes contribute to immunopathology in COVID-19. <i>Nature Communications</i> , 2022, 13, .	12.8	13
1415	Permissive omicron breakthrough infections in individuals with binding or neutralizing antibodies to ancestral SARS-CoV-2. <i>Vaccine</i> , 2022, 40, 5868-5872.	3.8	3

#	ARTICLE	IF	CITATIONS
1416	SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals. <i>Nature Communications</i> , 2022, 13, .	12.8	74
1417	Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern. <i>IScience</i> , 2022, 25, 105193.	4.1	7
1419	mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. <i>Vaccine</i> , 2022, 40, 6114-6124.	3.8	37
1420	Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	14
1421	Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster. <i>Vaccine: X</i> , 2022, 12, 100221.	2.1	2
1422	Novel reverse transcription-multiple inner primer loop-mediated isothermal amplification (RT-MIPLAMP) for visual and sensitive detection of SARS-CoV-2. <i>Analytical Methods</i> , 2022, 14, 5012-5018.	2.7	5
1423	Current strategy of SARS-CoV-2 molecular detection. <i>Analytical Methods</i> , 0, , .	2.7	0
1424	Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents. <i>Vaccines</i> , 2022, 10, 1646.	4.4	4
1425	SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. <i>Cell Reports</i> , 2022, 41, 111496.	6.4	20
1426	A combined fine needle aspiration and spectral flow cytometry approach to assess human germinal center responses to SARS-CoV-2 vaccination. <i>STAR Protocols</i> , 2022, 3, 101840.	1.2	3
1427	Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. <i>Science</i> , 2022, 378, .	12.6	141
1428	Optimizing the implementation of a participant-collected, mail-based SARS-CoV-2 serological survey in university-affiliated populations: lessons learned and practical guidance. <i>BMC Public Health</i> , 2022, 22, .	2.9	0
1429	A Rapid SARS-CoV-2 Nucleocapsid Protein Profiling Assay with High Sensitivity Comparable to Nucleic Acid Detection. <i>Analytical Chemistry</i> , 2022, 94, 14627-14634.	6.5	9
1430	Pandemic's silver lining. <i>MAbs</i> , 2022, 14, .	5.2	1
1431	Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	2
1432	Nucleic Acid Vaccines against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1849.	4.4	10
1433	The Performances of Three Commercially Available Assays for the Detection of SARS-CoV-2 Antibodies at Different Time Points Following SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 2196.	3.3	0
1434	Simultaneous Rapid Nucleic Acid and Protein Detection in a Lateral Chromatography Chip for COVID-19 Diagnosis. <i>ACS Omega</i> , 2022, 7, 38409-38416.	3.5	1

#	ARTICLE	IF	CITATIONS
1435	Serological response after anti-SARS-CoV-2 BNT162b2 vaccine in IBD patients on biological therapy: a monocentric case-control study. <i>Minerva Gastroenterology</i> , 0, , .	0.5	0
1437	Comparable diagnostic accuracy of SARS-CoV-2 Spike RBD and N-specific IgG tests to determine pre-vaccination nation-wide baseline seroprevalence in Mexico. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
1439	Ultrafast one-minute electronic detection of SARS-CoV-2 infection by 3CLpro enzymatic activity in untreated saliva samples. <i>Nature Communications</i> , 2022, 13, .	12.8	15
1440	Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
1441	Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020â€“21. <i>PLoS ONE</i> , 2022, 17, e0265478.	2.5	9
1442	Production of the SARS-CoV-2 Spike protein and its Receptor Binding Domain in plant cell suspension cultures. <i>Frontiers in Plant Science</i> , 0, 13, .	3.6	6
1443	Development of mRNA vaccines against respiratory syncytial virus (RSV). <i>Cytokine and Growth Factor Reviews</i> , 2022, 68, 37-53.	7.2	23
1445	Distribution characteristics of SARS-CoV-2 IgM/IgG in false-positive results detected by chemiluminescent immunoassay. <i>Open Life Sciences</i> , 2022, 17, 1487-1496.	1.4	0
1446	The role of physical activity in the clinical outcomes of people diagnosed with Covid-19: A systematic review. , 2022, 1, 100007.		2
1447	Design and optimization of an IgG human ELISA assay reactive to recombinant RBD SARS-CoV-2 protein. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 7933-7948.	3.6	3
1448	Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients. <i>IScience</i> , 2022, 25, 105608.	4.1	2
1449	A luciferase based automated assay for rapid and sensitive detection of SARS-CoV-2 antibodies. <i>Analytica Chimica Acta</i> , 2023, 1238, 340633.	5.4	2
1450	Optimization of purification conditions and study of antigenic properties of recombinant nucleocapsid protein of different SARS-CoV-2 strains. <i>Meditinskii Akademicheskii Zhurnal</i> , 2022, 2, 235-241.	0.2	1
1451	High prevalence of SARS-CoV-2 antibodies in pregnant women after the second wave of infections in the inner-city of Johannesburg, Gauteng Province, South Africa. <i>International Journal of Infectious Diseases</i> , 2022, 125, 241-249.	3.3	3
1452	Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1931.	4.4	1
1453	Development and evaluation of low-volume tests to detect and characterize antibodies to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
1454	Interferon-Î» treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. <i>Nature Communications</i> , 2022, 13, .	12.8	14
1455	Antibody tests for identification of current and past infection with SARS-CoV-2. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	32

#	ARTICLE	IF	CITATIONS
1456	Antibody Levels Poorly Reflect on the Frequency of Memory B Cells Generated following SARS-CoV-2, Seasonal Influenza, or EBV Infection. <i>Cells</i> , 2022, 11, 3662.	4.1	13
1457	Development of ELISA-based diagnostic methods for the detection of haemorrhagic septicaemia in animals. <i>Journal of Microbiological Methods</i> , 2023, 204, 106652.	1.6	1
1458	Paper-based multi-well depletion ELISA. <i>Lab on A Chip</i> , 2023, 23, 251-260.	6.0	2
1459	CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults. <i>Immunobiology</i> , 2023, 228, 152304.	1.9	2
1461	Simultaneous detection of antibody responses to multiple SARS-CoV-2 antigens by a Western blot serological assay. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 8183-8194.	3.6	0
1462	A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
1463	CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses. <i>Viruses</i> , 2022, 14, 2665.	3.3	2
1464	Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2897-2925.	12.0	1
1465	SARS-PLEX: Multiplex Serological ELISA with a Holistic Approach. <i>Viruses</i> , 2022, 14, 2593.	3.3	0
1466	Multiplexed evaluation of immunity against SARS-CoV-2 variants using surface enhanced fluorescence from a nanostructured plasmonic chip. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	9.1	3
1467	SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF- $\beta$ 2 signaling. <i>Nature Communications</i> , 2022, 13, .	12.8	18
1468	Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. <i>Nature</i> , 2023, 613, 735-742.	27.8	38
1471	Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. <i>Scientific Reports</i> , 2022, 12, .	3.3	11
1472	The Role of Advanced Technologies against COVID-19: Prevention, Detection, and Treatments. <i>Current Stem Cell Research and Therapy</i> , 2023, 18, 800-828.	1.3	0
1473	Impact of prenatal COVID-19 vaccination on delivery and neonatal outcomes: Results from a New York City cohort. <i>Vaccine</i> , 2023, 41, 649-656.	3.8	8
1474	Improved Expression of SARS-CoV-2 Spike RBD Using the Insect Cell-Baculovirus System. <i>Viruses</i> , 2022, 14, 2794.	3.3	1
1475	An ultrasensitive fluorescence aptasensor for SARS-CoV-2 antigen based on hyperbranched rolling circle amplification. <i>Talanta</i> , 2023, 255, 124221.	5.5	6
1477	Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2. <i>Biomedicines</i> , 2023, 11, 160.	3.2	1

#	ARTICLE	IF	CITATIONS
1478	Prevaccination Glucose Time in Range Correlates With Antibody Response to SARS-CoV-2 Vaccine in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, e474-e479.	3.6	1
1480	Prevalent and immunodominant CD8 Tâ€cell epitopes are conserved in SARS-CoV-2 variants. <i>Cell Reports</i> , 2023, 42, 111995.	6.4	12
1481	RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	1
1482	Nigeria healthcare worker SARS-CoV-2 serology study: Results from a prospective, longitudinal cohort. <i>PLOS Global Public Health</i> , 2023, 3, e0000549.	1.6	0
1483	Kinetics of Covid-19 antibodies in terms of titre and duration among healthcare workers: A longitudinal study. <i>The National Medical Journal of India</i> , 0, 35, 201-205.	0.3	0
1484	Screening and confirmation tests for SARS-CoV-2: benefits and drawbacks. <i>Beni-Suef University Journal of Basic and Applied Sciences</i> , 2023, 12, .	2.0	5
1486	Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens. <i>IScience</i> , 2023, 26, 105957.	4.1	15
1487	Stable production of recombinant SARS-CoV-2 receptor-binding domain in mammalian cells with co-expression of a fluorescent reporter and its validation as antigenic target for COVID-19 serology testing. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 37, e00780.	4.4	3
1490	Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. <i>Npj Vaccines</i> , 2022, 7, .	6.0	19
1491	Emerging Landscape of SARS-CoV-2 Variants and Detection Technologies. <i>Molecular Diagnosis and Therapy</i> , 2023, 27, 159-177.	3.8	6
1492	Laboratory-Based SARS-CoV-2 Receptor Binding Domain Serologic Assays Perform with Equivalent Sensitivity and Specificity to Commercial FDA-EUA Approved Tests. <i>Viruses</i> , 2023, 15, 106.	3.3	3
1493	Aptamer-Linked Photonic Crystal Assay for High-Throughput Screening of HIV and SARS-CoV-2. <i>Analytical Chemistry</i> , 0, , .	6.5	0
1494	SARS-CoV-2 infection history and antibody response to three COVID-19 mRNA vaccine doses. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	2
1495	Label-free impedimetric immunosensor for point-of-care detection of COVID-19 antibodies. <i>Microsystems and Nanoengineering</i> , 2023, 9, .	7.0	18
1496	The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies among staff and students in a Cameroon University. <i>Journal of Public Health in Africa</i> , 2023, 14, .	0.4	2
1497	Cell-Free Dot Blot: an Ultra-Low-Cost and Practical Immunoassay Platform for Detection of Anti-SARS-CoV-2 Antibodies in Human and Animal Sera. <i>Microbiology Spectrum</i> , 2023, 11, .	3.0	1
1498	Comparative Characterization of Diverse DNA Aptamers for Recognition of Spike Proteins of Multiple SARSâ€CoVâ€2 Variants. <i>Analysis &amp; Sensing</i> , 2023, 3, .	2.0	0
1499	Chemically Amplified Multiplex Detection of SARSâ€CoVâ€2 and Influenza A and B Viruses via Paintâ€Programmed Lateral Flow Assays. <i>Small</i> , 2023, 19, .	10.0	3

#	ARTICLE	IF	CITATIONS
1500	The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial. <i>International Journal of Infectious Diseases</i> , 2023, 130, 52-59.	3.3	2
1501	Gold-silver alloy hollow nanoshells-based lateral flow immunoassay for colorimetric, photothermal, and SERS tri-mode detection of SARS-CoV-2 neutralizing antibody. <i>Analytica Chimica Acta</i> , 2023, 1255, 341102.	5.4	14
1502	Development of SARS-CoV-2 neutralizing antibody detection assay by using recombinant plant-produced proteins. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2023, 38, e00796.	4.4	2
1503	COVID-19: Impact, Diagnosis, Management and Phytoremediation. <i>Current Traditional Medicine</i> , 2023, 9, .	0.4	0
1504	Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study. <i>Clinical and Experimental Nephrology</i> , 0, , .	1.6	0
1505	Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy. <i>Acta Crystallographica Section D: Structural Biology</i> , 2023, 79, 111-121.	2.3	9
1506	Ultrasensitive lateral-flow assays via plasmonically active antibody-conjugated fluorescent nanoparticles. <i>Nature Biomedical Engineering</i> , 2023, 7, 1556-1570.	22.5	27
1507	Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers. <i>Viruses</i> , 2023, 15, 426.	3.3	3
1508	Performance estimation of two in-house ELISA assays for COVID-19 surveillance through the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulin isotypes. <i>PLoS ONE</i> , 2023, 18, e0270388.	2.5	1
1509	Autoantibodies are highly prevalent in nonâ€SARS-CoV-2 respiratory infections and critical illness. <i>JCI Insight</i> , 2023, 8, .	5.0	9
1510	Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cellâ€targeted therapy. <i>JCI Insight</i> , 2023, 8, .	5.0	0
1512	Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. <i>Nature Communications</i> , 2023, 14, .	12.8	14
1513	Effect of acetic acid inactivation of SARS-CoV-2. <i>PLoS ONE</i> , 2023, 18, e0276578.	2.5	8
1514	Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines. <i>Scientific Reports</i> , 2023, 13, .	3.3	6
1515	Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	1
1517	Using SARS-CoV-2 Antibody Testing in COVID-19 Research. <i>American Journal of Medicine</i> , 2023, , .	1.5	0
1518	An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	2
1519	Immunological Findings in a Group of Individuals Who Were Poor or Non-Responders to Standard Two-Dose SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2023, 11, 461.	4.4	2

#	ARTICLE	IF	CITATIONS
1520	A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. <i>Cell Reports Medicine</i> , 2023, 4, 100971.	6.5	4
1521	RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2. <i>Viruses</i> , 2023, 15, 555.	3.3	1
1522	S-RBD IgG Response After Second Dose of CoronaVac; Prospective Study on Health Workers. <i>Indonesian Journal of Clinical Pathology</i> , 2023, 29, 74-80.	0.1	0
1523	Diagnostic TR-FRET assays for detection of antibodies in patient samples. <i>Cell Reports Methods</i> , 2023, 3, 100421.	2.9	0
1524	Development and validation of a rapid and easy-to-perform point-of-care lateral flow immunoassay (LFIA) for the detection of SARS-CoV-2 spike protein. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
1525	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
1526	Capabilities of Double-Resonance LPG and SPR Methods for Hypersensitive Detection of SARS-CoV-2 Structural Proteins: A Comparative Study. <i>Biosensors</i> , 2023, 13, 318.	4.7	3
1527	Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers. <i>Frontiers in Microbiology</i> , 0, 14, .	3.5	1
1528	Discriminating promiscuous from target-specific autoantibodies in COVID-19. <i>European Journal of Immunology</i> , 2023, 53, .	2.9	6
1529	Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. <i>Journal of Clinical Investigation</i> , 2023, 133, .	8.2	4
1530	Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and Marines. <i>Journal of Infectious Diseases</i> , 2023, 228, 149-159.	4.0	3
1531	Seroconversion in COVID-19 Infection and Comparison of Antibody Responses in Symptomatic Versus Asymptomatic Individuals. <i>Journal of Pure and Applied Microbiology</i> , 2023, 17, 590-596.	0.9	0
1532	Comparison of vector elements and process conditions in transient and stable suspension HEK293 platforms using SARS-CoV-2 receptor binding domain as a model protein. <i>BMC Biotechnology</i> , 2023, 23, .	3.3	1
1533	Occupational Risk Factors for SARS-CoV-2 Seropositivity in Healthcare Workers. <i>Journal of Occupational and Environmental Medicine</i> , 2023, 65, 521-528.	1.7	2
1534	Active Enrichment of Nanoparticles for Ultra-Trace Point-of-Care COVID-19 Detection. <i>Analytical Chemistry</i> , 2023, 95, 5316-5322.	6.5	12
1535	Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. <i>Science Translational Medicine</i> , 2023, 15, .	12.4	15
1536	Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults. <i>Communications Medicine</i> , 2023, 3, .	4.2	3
1538	A urine-based ELISA with recombinant non-glycosylated SARS-CoV-2 spike protein for detecting anti-SARS-CoV-2 spike antibodies. <i>Scientific Reports</i> , 2023, 13, .	3.3	1

#	ARTICLE	IF	CITATIONS
1539	Plant-based biopharmaceutical engineering. , 2023, 1, 426-439.		24
1540	A pilot study: Validation of dried blood spots (DBS) to assess SARS-CoV2 IgG antibody immunoassays in underserved minority population. Heliyon, 2023, 9, e14729.	3.2	0
1541	Genetically engineered pair of cells for serological testing and its application for SARS-CoV-2. Bioengineering and Translational Medicine, 2023, 8, .	7.1	1
1542	Robust SARS-CoV-2 T cell responses with common TCR $\alpha$ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. Cell Reports Medicine, 2023, 4, 101017.	6.5	7
1543	A new multiplex SARS-CoV-2 antigen microarray showed correlation of IgG, IgA, and IgM antibodies from patients with COVID-19 disease severity and maintenance of relative IgA and IgM antigen binding over time. PLoS ONE, 2023, 18, e0283537.	2.5	3
1544	At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study. Eurosurveillance, 2023, 28, .	7.0	2
1545	A RT-qPCR test targeting the conserved 5'UTR of SARS-CoV-2 overcomes major shortcomings of the first WHO-recommended RT-qPCR test. , 2023, 3, 818-846.		0
1546	Well-Defined Heparin Mimetics Can Inhibit Binding of the Trimeric Spike of SARS-CoV-2 in a Length-Dependent Manner. JACS, 2023, 3, 1185-1195.	7.9	5
1547	Epitopes Displayed in a Cyclic Peptide Scaffold Bind SARS-CoV-2 Antibodies. ChemBioChem, 2023, 24, .	2.6	0
1548	Immune profiling of SARS-CoV-2 infection during pregnancy reveals NK cell and T cell perturbations. JCI Insight, 2023, 8, .	5.0	4
1549	Structural basis of spike RBM-specific human antibodies counteracting broad SARS-CoV-2 variants. Communications Biology, 2023, 6, .	4.4	0
1550	Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. Microorganisms, 2023, 11, 1000.	3.6	2
1551	Multiplexed on-yeast serological assay for immune escape screening of SARS-CoV-2 variants. IScience, 2023, 26, 106648.	4.1	1
1552	An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies. AIMS Microbiology, 2023, 9, 375-401.	2.2	4
1554	A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nature Communications, 2023, 14, .	12.8	21
1555	Longitudinal analysis of SARS-CoV-2 infection and vaccination in the LA-SPARTA cohort reveals increased risk of infection in vaccinated Hispanic participants. Frontiers in Immunology, 0, 14, .	4.8	0
1556	Nonlinear interdependence of the results of measuring anti-SARS-CoV-2 IgG levels using Abbott and Euroimmun test systems. Journal of Clinical Virology, 2023, , 105448.	3.1	1
1557	Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity. Communications Biology, 2023, 6, .	4.4	8

#	ARTICLE	IF	CITATIONS
1558	Modulation of the Immune Response to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination by Nonsteroidal Anti-Inflammatory Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 386, 198-204.	2.5	2
1559	An improved method of global dynamics: Analyzing the COVID-19 model with time delays and exposed infection. <i>Chaos</i> , 2023, 33, .	2.5	1
1560	Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand. <i>Vaccines</i> , 2023, 11, 884.	4.4	1
1561	A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes. <i>Applied Microbiology and Biotechnology</i> , 2023, 107, 3429-3441.	3.6	1
1562	Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models. <i>Vaccines</i> , 2023, 11, 1006.	4.4	1
1563	SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C compared to COVID-19. <i>Journal of Experimental Medicine</i> , 2023, 220, .	8.5	6
1564	MultiSero: An Open-Source Multiplex-ELISA Platform for Measuring Antibody Responses to Infection. <i>Pathogens</i> , 2023, 12, 671.	2.8	0
1565	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Titer Levels in Pregnant Individuals After Infection, Vaccination, or Both. <i>Obstetrics and Gynecology</i> , 2023, 141, 1199-1202.	2.4	0
1566	Detection of SARS-CoV-2 Antibodies in Immunoglobulin Products. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 2534-2541.e2.	3.8	1
1567	Aqueous cannabidiol $\beta$ -cyclodextrin complexed polymeric micelle nasal spray to attenuate in vitro and ex vivo SARS-CoV-2-induced cytokine storms. <i>International Journal of Pharmaceutics</i> , 2023, 640, 123035.	5.2	2
1568	Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. <i>Nature Immunology</i> , 2023, 24, 966-978.	14.5	7
1569	Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy. <i>IScience</i> , 2023, 26, 107056.	4.1	0
1570	Glyco engineered pentameric SARS-CoV-2 IgMs show superior activities compared to IgG1 orthologues. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
1571	Standardization of in-house anti-IgG and IgA ELISAs for the detection of COVID-19. <i>PLoS ONE</i> , 2023, 18, e0287107.	2.5	2
1572	Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. <i>IScience</i> , 2023, 26, 107084.	4.1	2
1573	Microfluidic Immunoassay Reveals Systems Level Association with COVID-19 Pathology and Vaccine Protection. <i>Small Methods</i> , 2023, 7, .	8.6	3
1574	CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes. <i>Science Advances</i> , 2023, 9, .	10.3	0
1575	Recent progress on rapid diagnosis of COVID-19 by point-of-care testing platforms. <i>Chinese Chemical Letters</i> , 2024, 35, 108688.	9.0	8

#	ARTICLE	IF	CITATIONS
1576	Automating Prognostics and Prevention of Errors, Conflicts, and Disruptions. Springer Handbooks, 2023, , 509-531.	0.6	2
1578	Using a multiplex serological assay to estimate time since SARS-CoV-2 infection and past clinical presentation in malagasy patients. Heliyon, 2023, 9, e17264.	3.2	1
1579	Development of a Series of Neutralizing Nanobodies against SARS-CoV-2 Spike Protein. Molecular Biology, 2023, 57, 502-511.	1.3	1
1580	A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination. Vaccine, 2023, 41, 5037-5044.	3.8	1
1581	Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis. Leukemia and Lymphoma, 0, , 1-5.	1.3	1
1582	Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures. Journal of Nanobiotechnology, 2023, 21, .	9.1	3
1583	Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	3
1584	Unique molecular signatures sustained in circulating monocytes and regulatory T cells in convalescent COVID-19 patients. Clinical Immunology, 2023, 252, 109634.	3.2	6
1585	Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis. Science Immunology, 2023, 8, .	11.9	24
1587	Memory B cell development elicited by mRNA booster vaccinations in the elderly. Journal of Experimental Medicine, 2023, 220, .	8.5	2
1588	Blood group A enhances SARS-CoV-2 infection. Blood, 2023, 142, 742-747.	1.4	10
1590	Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees. Vaccines, 2023, 11, 1183.	4.4	1
1591	SARS-CoV-2 antibody response duration and neutralization following natural infection. Journal of Clinical Virology Plus, 2023, 3, 100158.	1.0	1
1592	Single-molecule immunoassay technology: Recent advances. Talanta, 2023, 265, 124903.	5.5	3
1593	Persistent immune and clotting dysfunction detected in saliva and blood plasma after COVID-19. Heliyon, 2023, 9, e17958.	3.2	2
1594	Soluble <sc>SARSâ€CoV</sc>â€2 <sc>RBD</sc> and human <sc>ACE2</sc> peptidase domain produced in <i>Drosophila</i> <sc>S2</sc> cells show functions evoking virusâ€cell interface. Protein Science, 0, , .	7.6	0
1595	New detection method of SARS-CoV-2 antibodies toward a point-of-care biosensor. Frontiers in Bioengineering and Biotechnology, 0, 11, .	4.1	0
1596	Machine-learning-aided multiplexed nanoplasmonic biosensor for COVID-19 population immunity profiling. Sensors & Diagnostics, 2023, 2, 1186-1198.	3.8	2

#	ARTICLE	IF	CITATIONS
1597	A design strategy to generate a SARS-CoV-2 RBD vaccine that abrogates ACE2 binding and improves neutralizing antibody responses. European Journal of Immunology, 2023, 53, .	2.9	2
1598	Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters. Nature Communications, 2023, 14, .	12.8	6
1599	SARS-CoV-2 Serological Investigation of White-Tailed Deer in Northeastern Ohio. Viruses, 2023, 15, 1603.	3.3	0
1600	Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers. Frontiers in Public Health, 0, 11, .	2.7	1
1601	The natural tannins oligomeric proanthocyanidins and punicalagin are potent inhibitors of infection by SARS-CoV-2. ELife, 0, 12, .	6.0	2
1602	Recent Advances in DNA Nanotechnology-Enabled Biosensors for Virus Detection. Biosensors, 2023, 13, 822.	4.7	5
1603	Chronic False Positive Rapid Plasma Reagin (RPR) Tests Induced by COVID-19 Vaccination. Covid, 2023, 3, 1304-1309.	1.5	0
1604	Developmental and reproductive safety of Advax-CpG55.2 <sub>adjuv</sub> adjuvanted COVID-19 and influenza vaccines in mice. Vaccine, 2023, 41, 6093-6104.	3.8	2
1605	Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5–11 Years in a Multisite Prospective Cohort Study, September 2021–September 2022. Open Forum Infectious Diseases, 2023, 10, .	0.9	0
1606	Interchangeability of the Assays Used to Assess the Activity of Anti-SARS-CoV-2 Monoclonal Antibodies. Viruses, 2023, 15, 1698.	3.3	0
1607	A COVID19-selective pH-paper test: Ultrafast and highly accurate antibody-free viral detection in native saliva. Chemical Engineering Journal, 2023, 475, 146304.	12.7	0
1608	Broad spectrum SARS-CoV-2-specific immunity in hospitalized First Nations peoples recovering from COVID-19. Immunology and Cell Biology, 0, , .	2.3	0
1609	A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses. Nature Biomedical Engineering, 0, , .	22.5	5
1610	IgG3 subclass antibodies recognize antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent binding. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	2
1611	Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2. Cell Reports Methods, 2023, 3, 100565.	2.9	1
1612	Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature. Frontiers in Immunology, 0, 14, .	4.8	7
1613	Maternal Immunization During the Second Trimester with BNT162b2 mRNA Vaccine Induces a Robust IgA Response in Human Milk: A Prospective Cohort Study. American Journal of Clinical Nutrition, 2023, 118, 572-578.	4.7	0
1614	Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance. Vaccine: X, 2023, 15, 100367.	2.1	0

#	ARTICLE	IF	CITATIONS
1616	Factors influencing neutralizing antibody response to the original SARS-CoV-2 virus and the Omicron variant in a high vaccination coverage country, a population-based study. <i>Vaccine</i> , 2023, 15, 100372.	2.1	0
1617	Investigating the impact of prior COVID-19 on IgG antibody and interferon $\gamma$ responses after BBIBP-CorV vaccination in a disease endemic population: A prospective observational study. <i>Health Science Reports</i> , 2023, 6, .	1.5	1
1618	Kinetics of humoral response to <i>Pasteurella multocida</i> in buffaloes against combined foot-and-mouth+haemorrhagic septicaemia vaccine. <i>Indian Journal of Animal Sciences</i> , 2023, 93, .	0.2	0
1620	Rapid COVID-19 immunity screening by machine learning aided multiplexed nanoplasmonic biosensor. , 2023, , .		0
1621	Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies. <i>Environmental Research</i> , 2023, 239, 117297.	7.5	1
1622	Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1624	Applications of time series analysis in epidemiology: Literature review and our experience during COVID-19 pandemic. <i>World Journal of Clinical Cases</i> , 0, 11, 6974-6983.	0.8	0
1625	Application of concanavalin A as a new diagnostic strategy for SARS-COV-2 spike protein. <i>Biochemical Engineering Journal</i> , 2024, 201, 109116.	3.6	0
1626	Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants. <i>Vaccine</i> , 2023, 41, 7116-7128.	3.8	2
1627	Molecular testing in emerging infectious diseases. , 2024, , 175-198.		0
1628	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
1629	SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
1630	Dual-Antigen Subunit Vaccine Nanoparticles for Scrub Typhus. <i>Pathogens</i> , 2023, 12, 1390.	2.8	0
1631	RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity. <i>Cell Reports Medicine</i> , 2023, 4, 101266.	6.5	2
1632	The Detection of SARS-CoV-2 Antibodies in an Exposed Human Population Is Biased by the Immunoassay Used: Implications in Serosurveillance. <i>Pathogens</i> , 2023, 12, 1360.	2.8	0
1633	Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1634	Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.9	1
1635	A bead-based multiplex assay covering all coronaviruses pathogenic for humans for sensitive and specific surveillance of SARS-CoV-2 humoral immunity. <i>Scientific Reports</i> , 2023, 13, .	3.3	0

#	ARTICLE	IF	CITATIONS
1636	Characterizing the evolving SARS-CoV-2 seroprevalence in urban and rural Malawi between February 2021 and April 2022: A population-based cohort study. <i>International Journal of Infectious Diseases</i> , 2023, 137, 118-125.	3.3	1
1637	Serum antibody levels to SARS-CoV-2 receptor-binding domain (RBD) in convalescent patients and vaccinated individuals of northern Nevada. <i>PLoS ONE</i> , 2023, 18, e0288713.	2.5	0
1638	Atualiza��o Diagn�stica para a Covid-19. ID on Line <i>REVISTA DE PSICOLOGIA</i> , 2023, 17, 351-384.	0.1	0
1639	Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19. <i>IJID Regions</i> , 2024, 10, 1-8.	1.3	0
1641	Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children. <i>Vaccine: X</i> , 2023, 15, 100414.	2.1	0
1642	mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infection. <i>IScience</i> , 2023, 26, 108572.	4.1	2
1643	Immunogenicity and Protective Efficacy of Nucleic Acid-Based Vaccines Against COVID-19: A Systematic Review. <i>Molecular Biotechnology</i> , 0, , .	2.4	0
1644	Examining the effect of SARS-CoV-2 pandemic-induced stress and anxiety on humoral immunity in healthcare workers. <i>Journal of Occupational and Environmental Medicine</i> , 0, , .	1.7	0
1645	Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants. <i>Immunity</i> , 2023, 56, 2803-2815.e6.	14.3	2
1646	Application of a Receptor-Binding-Domain-Based Simple Immunoassay for Assessing Humoral Immunity against Emerging SARS-CoV-2 Virus Variants. <i>Biomedicines</i> , 2023, 11, 3193.	3.2	0
1648	State-of-the-Art Virology Research in Norway. <i>Viruses</i> , 2023, 15, 2383.	3.3	0
1649	Surrogate Virus Neutralisation Test Based on Nanoluciferase-Tagged Antigens to Quantify Inhibitory Antibodies against SARS-CoV-2 and Characterise Omicron-Specific Reactivity in a Vaccination Cohort. <i>Vaccines</i> , 2023, 11, 1832.	4.4	1
1650	Quantitative microfluidic assay to measure neutralizing and total antibodies for SARS-CoV-2. <i>Sensors and Actuators B: Chemical</i> , 2024, 403, 135093.	7.8	0
1651	Tracking SARS-CoV-2 seropositivity in rural communities using blood-fed mosquitoes: a proof-of-concept study. , 0, 3, .		0
1652	The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from all <i>Orthocoronavirinae</i> genera. <i>MBio</i> , 2024, 15, .	4.1	1
1653	Simple, Rapid, and Highly Sensitive Magnetic Beads ELISA for Detection of SARS CoV-2 Antibodies (IgG) in Human Plasma Samples as a Point of Care Assay. <i>Mikrobiolohichny� Zhurnal</i> , 2023, 85, 61-65.	0.6	0
1654	Expression and purification of the receptor�binding domain of <scp>SARS�CoV</scp>��2 spike protein in mammalian cells for immunological assays. <i>FEBS Open Bio</i> , 2024, 14, 380-389.	2.3	0
1655	Rapid, Multispecies Detection of SARS-CoV-2 Antibodies via a Meta-Surface Plasmon Resonance Biosensor. <i>Transboundary and Emerging Diseases</i> , 2024, 2024, 1-14.	3.0	0

#	ARTICLE	IF	CITATIONS
1656	Performance of plant-produced RBDs as SARS-CoV-2 diagnostic reagents: a tale of two plant platforms. <i>Frontiers in Plant Science</i> , 0, 14, .	3.6	0
1657	Immunoglobulin A response to SARS-CoV-2 infection and immunity. <i>Heliyon</i> , 2024, 10, e24031.	3.2	0
1658	A magnetic-enhanced FRET biosensor for simultaneous detection of multiple antibodies. <i>Smart Materials in Medicine</i> , 2024, 5, 196-206.	6.7	0
1659	Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1660	Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters. <i>PLoS Pathogens</i> , 2024, 20, e1011805.	4.7	1
1661	COVID-19 laboratory diagnosis. , 2024, , 2727-2741.		0
1662	SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice. <i>Viruses</i> , 2024, 16, 185.	3.3	0
1663	The Anti-SARS-CoV-2 IgG1 and IgG3 Antibody Isotypes with Limited Neutralizing Capacity against Omicron Elicited in a Latin Population a Switch toward IgG4 after Multiple Doses with the mRNA Pfizer“BioNTech Vaccine. <i>Viruses</i> , 2024, 16, 187.	3.3	0
1664	Paradigm of immune dysregulation in coronavirus disease-2019 infection. <i>Exploration of Immunology</i> , 0, , 1-33.	0.3	0
1665	The Age of the Expert“COVID-19, Expertise, and Conflicts of Interest in Austrian Media Reporting. <i>Journalism and Media</i> , 2024, 5, 163-188.	1.5	0
1666	Immune response to SARS-CoV-2 variants after immunization with different vaccines in Mexico. <i>Epidemiology and Infection</i> , 2024, 152, .	2.1	0
1667	A label-free aptasensing method for detecting SARS-CoV-2 virus antigen by using dumbbell probe-mediated circle-to-circle amplification. <i>Analytical and Bioanalytical Chemistry</i> , 2024, 416, 1961-1970.	3.7	0
1668	Dual coiled-coil protein domain mimic and drug delivery vehicle for SARS-CoV-2. <i>Biochemical Engineering Journal</i> , 2024, 205, 109261.	3.6	0
1669	Anti-SARS-CoV-2 Antibody Response Among Spectators of Amir Cup 2020 With a History of Recovery From COVID-19 in Qatar: A Historic Cohort Study. <i>Cureus</i> , 2024, , .	0.5	0
1670	SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. <i>Immunity</i> , 2024, 57, 587-599.e4.	14.3	0
1671	Open-source milligram-scale, four channel, automated protein purification system. <i>PLoS ONE</i> , 2024, 19, e0297879.	2.5	0
1672	Rapid simulation of glycoprotein structures by grafting and steric exclusion of glycan conformer libraries. <i>Cell</i> , 2024, 187, 1296-1311.e26.	28.9	0
1673	Engineered two-dimensional nanomaterials based diagnostics integrated with internet of medical things (IoMT) for COVID-19. <i>Chemical Society Reviews</i> , 2024, 53, 3774-3828.	38.1	0

#	ARTICLE	IF	CITATIONS
1674	Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity, 2024, 57, 912-925.e4.	14.3	0
1675	Seroprevalence of IgG Antibodies Against SARS-CoV-2 N Protein Among Vaccinated and Unvaccinated Subjects in Lahore, Pakistan. Acta Medica Bulgarica, 2024, 51, 30-35.	0.1	0
1676	Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines. Vaccines, 2024, 12, 326.	4.4	0
1677	Nanotherapeutics targeting autophagy regulation for improved cancer therapy. Acta Pharmaceutica Sinica B, 2024, , .	12.0	0
1678	SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5. Cell Reports Medicine, 2024, 5, 101474.	6.5	0